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ABSTRACT 
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The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Dr. Alexander Arnold 
 
 
 
The vitamin D receptor (VDR) is a ligand-dependent transcription factor, which belongs 
to the nuclear receptor superfamily. VDR-mediated gene regulation is governed by 
coregulators (coactivators and corepressors). VDR coregulator binding inhibitors (CBIs), 
which were discovered using high throughput screening (HTS), were evaluated using 
cell-based assays and biochemical assays to determine their ability to inhibit the 
interaction between VDR and steroid receptor coactivator-2 (SRC-2). Determining their 
ability to inhibit the VDR-SRC-2 interaction can lead to the development of novel and 
safer pharmaceutical treatments for VDR-related disorders, such as cancer, autoimmune 
diseases, and cardiovascular disease; therefore, the study of transcription, toxicity, and 
protein-protein interactions are critical to the development of pharmaceutical treatments.  
The methods used to study CBIs include a cell-based transcription assay, which 
was based on the formation of β-lactamase in the Hek 293T cell line. The readout of this 
assay was fluorescence resonance energy transfer (FRET) of a cell-permeable substrate in 
the event of transcription inhibition, and a blue fluorescent signal in the event of 
iii 
 
transcription activation. Active CBIs, such as compound WL052410G (31b), exhibit a 
reduced blue to green fluorescent ratio.  
A luciferase-based viability assay, which detected ATP levels from metabolically 
active Hek 293T cells, was used to determine the toxicity of the CBIs, in hopes of 
detecting partial toxicity for pharmaceutical targets of VDR, such as compound 
WL052410G (31b).  
Different co-immunoprecipitation pull-down assays were developed to precipitate 
and isolate target proteins, such as VDR, SRC-2, and SRC-2-3, using affinity-based 
tagging, in order to determine the ability of CBIs to disrupt the protein-protein interaction 
between VDR and SRC-2 coactivator. The VDR-SRC-2 interaction was visualized using 
a fluorescently tagged antibody, which was realized using a laser imager. 
The most active compounds for all the assays performed belong to a series of 3-
indolyl-methanamines and include a highly selective and active compound, WL052410G 
(31b). 
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In an unligated state, VDR binds corepressor proteins, such as the nuclear 
receptor corepressor (NCoR) and the silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT), which repress the transcription of VDR target genes.9 NCoRs 
have short consensus sequences that are similar to that of coactivators, which are 
discussed later in this chapter. The consensus sequence of these corepressors is ΦxxΦΦ, 
where Φ is isoleucine or leucine, and x is any amino acid. 10, 11 This sequence forms an α-
helix, which is one turn longer than the coactivator helix. The formation of this helix 
allows for corepressor binding to the AF-2 domain without helix 12 contacting the VDR-
LBD.  
Helix 12 projects away from the core of the VDR-LBD, allowing corepressors to 
stay docked and to negatively control the transcriptional machinery by relaying a 
repressive signal to maintain a closed chromatin structure, leaving the histones in the 
amino terminal tails in a charged state, which is tightly associated with DNA. 12, 13 
VDR binds corepressors to negatively modulate transcription through histone 
deacetylase activity. Deacetylase activity catalyzes the removal of acetyl groups from 
lysine residues to increase the positive charge on the histone, thus, strengthening the 
interactions between DNA and the histone. The deacetylation of the histones results in a 
compacted chromatin structure and prevents the RNA polymerase from initiating 
transcription. 
The AF-2 domain is where coactivators are able to interact with the VDR multi-
protein complex, which further modulates and activates VDR-mediated transcription by 
recruiting the assembly of transcriptional proteins. In the ligated state, helix 12 contacts 
the VDR-LBD, creating the AF-2 domain.  
5 
 
 
The creation of the AF-2 domain allows for positive modulation of transcription 
by modifying histone structure through acetyltransferases, which are recruited by 
coactivators, such as the steroid receptor coactivator (SRC), also known as the glutamate 
receptor interacting proteins (GRIP) family of coactivators, of which, the SRC-2 
coactivator plays a critical role for the experiments in this thesis. 14-16  
Histone acetyltransferases (HATs) are a class of enzymes involved in gene 
transcription through remodeling chromatin structure. HATs target histones are bound to 
DNA and catalyze the acetylation of lysine residues in the amino terminal tail of histones. 
The DNA is unwound, and then targeted by VDR-interacting protein (DRIP) complex.17, 
18
 DRIP is a protein complex which is required for the initiation of transcription.  
VDR binds DNA gene response elements, so that when the coactivators are 
recruited, the histone structure of the target genes can be modified. Coactivators, which 
usually contain several LxxLL (L is leucine and x is any amino acid) consensus 
sequences with different flanking amino acid residues called NR boxes, bind in the 
hydrophobic cleft of the AF-2 domain. The LxxLL consensus sequences form an 
amphipathic α-helix which fits into the hydrophobic pocket of the AF-2 domain on the 
VDR-LBD.8 
VDR coregulator binding inhibitors (VDR-CBIs) prevent the binding of 
corepressors or coactivators to the VDR. An inhibitor can bind to its target protein 
irreversibly through covalent bonding, or reversibly through either hydrophobic 
interactions, hydrogen bonds, or ionic interactions.  
VDR ligand agonists have been developed to treat metabolic bone diseases and 
proliferative skin disorders; however, only a limited number of VDR ligand antagonists 
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have been determined to allosterically inhibit the interactions between VDR and its 
coactivators.19-26 Direct inhibition of VDR-coactivator binding using small molecules was 
first reported by Mita et al.27 This novel approach helps determine the role of coregulators 
in gene regulation in the presence 1, 25-(OH)2D3. CBIs have been discovered for the 
estrogen receptor (ER), thyroid receptor (TR), androgen receptor (AR), and the 
peroxisome proliferator activated receptor (PPAR).28 The research described herein 
enabled the identification of the first irreversible and highly selective VDR-CBIs.29 
Small molecule inhibitors of protein-protein interactions are important tools in 
research and recently emerged as starting points for drug development. Identification of 
the molecular interaction between VDR and CBIs can provide insight to the development 
of novel and safer methods for nuclear hormone receptor ligand-based treatments, such as 
those for cancer; therefore, it is important to characterize these CBIs with regard to 
transcription and cytotoxicity. 
The compounds were evaluated for the inhibition of transcription and cytotoxicity 
using a fluorescence resonance energy transfer (FRET)-based assay and a luciferase 
assay, respectively. In addition, a co-immunoprecipitation (co-IP) and an immune-
detection pull-down assay were performed, in order to further prove the inhibition 
between VDR and SRC-2 coactivator was inhibited in a dose-dependent manner. One of 
the most promising inhibitors was based on the scaffold of 3-indolyl-methanamines.  
In addition, newly synthesized analogs of 3-indolyl-methanamines were studied 
for transcriptional activity, as well as cytotoxicity, and produced the first selective and 
irreversible VDR-CBI, compound WL052410G (31b). The transcriptional regulation of 
these compounds was studied using the VDR target gene, CYP24A1, in mammalian cells.  
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The cell-based assay was developed in 1998 and has been used widely for NRs, 
including AR, progesterone receptor (PR), mineralocorticoid receptor (MR), 
glucocorticoid receptor (GR), and both ER-α and ER-β receptors.30 These and other NRs 
bind various steroid-based ligands, which leads to the homodimerization of the NR and 
binding to specific promoter elements, in order to drive the expression of downstream NR 
genes, which control various cellular functions. Alterations in the function of these 
receptors lead to endocrine-related diseases, such as cancer and heart disease.  
For VDR, a Gal4-DBD and VDR-LBD fusion protein was cloned into an 
upstream activation sequence (UAS) and stably transfected into Hek 293T cells. In 
addition, a β-lactamase reporter gene, under transcriptional control of an upstream 
activation sequence (UAS-bla), was stably transfected. The assay used known agonists 
and antagonists in a dose-response format as controls, which demonstrate selective NR 
modulation. The assay was also able to identify and differentiate mixed and partial 
agonists and antagonists.  
The reason that partial agonists and antagonists have a more desirable drug effect 
than full agonists and antagonists is because they have fewer off-target side effects, due 
to their partial activity.31 These compounds can have different biological effects and 
alternative conformations of the receptor, which can result in differential recruitment or 
displacement of cofactors, as well as tissue-specific and promoter-selective expression of 
target genes.   
 A co-immunoprecipitation assay was performed as a secondary assay, in order to 
determine the inhibition between VDR and coactivators; therefore, E. coli cells were used 
for the expression and purification of the SRC-2 protein. Once the SRC-2 protein was 
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attached to a glutathione S-transferase (GST) bead, a pull-down assay was performed on 
varied concentrations of CBIs. This assay was then resolved using sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, blotted to a Western 
membrane, and VDR was detected using a fluorescently tagged secondary antibody. The 
assay was performed in this manner, in order to demonstrate that the CBI showed a dose-
response in competing with SRC-2 for VDR binding.  
  
Chapter 2: Cell Culture and Gene BLAzer Assay 
 
Chapter 2.1: HEP G2 Cells and Culture Methods of HEP G2 Cells 
Cell culture practice began on the human hepatocellular liver carcinoma (HEP G2) cell 
line. This cell line is commonly used to determine liver toxicity of small molecules.32 
First, the cells were thawed from liquid nitrogen, and a 1 mL fraction was pipetted into a 
cell culture flask containing 14 mL of recovery media, which was eagle’s minimum 
essential medium (EMEM from ATCC). EMEM consists of a balanced salt solution, non-
essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1500 mg/L 
sodium bicarbonate. The cells were placed in the sterile incubator at 37°C and 5 percent 
carbon dioxide until they reached 60 to 90 percent confluency.  
The cells were passaged by first aspirating the old growth media, and then by 
rinsing the cell flask with 10 mL of phosphate buffered saline (PBS), which rinsed away 
any dead cells. The cells were detached from the cell culture flask using 0.25 percent 
trypsin, which is described later in this chapter.33 The flask was incubated with the 
trypsin for 3 to 5 minutes at 37°C and 5 percent carbon dioxide in a sterile incubator. 
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After incubation, the cell suspension was mixed by pipette, in order to achieve a single 
cell suspension, and 1 mL of the suspension was introduced into new flasks containing 15 
mL of growth media, which was the same as the recovery media previously described, 
but with 10 percent fetal bovine serum (FBS) added to the recovery media. No further 
tests were conducted using this cell line.  
 
Chapter 2.2: Description of the Hek 293T Cell Line 
A commercially available, stably transfected, human embryonic kidney (Hek 293T) cell34 
line was cultured for use in the Gene BLAzer and Cell Titer-Glo assays.  
The Hek 293T cells contained the simian vacuolating (SV) virus 40 T-antigen 
origin of replication,35 which allowed for activated transient gene transcription and 
improved incorporation of foreign genes into the host genome.   
The commercially available Hek 293T cell line also contained 2 stably transfected 
plasmid vectors. The first plasmid vector was a chimeric vector bearing the ligand 
binding domain of VDR and the DNA binding domain of the Gal4 transcription factor 
(Figure 4).36 The second vector contained chimeric DNA assembled from a UAS 
response element and a β-lactamase gene (bla) (Figure 5).  
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Figure 4: Chimeric plasmid vector of VDR-LBD and Gal4-DBD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: β-lactamase and UAS chimeric plasmid vector. 
 
 
 
Gal4 is a yeast-specific transcription factor, which is a positive gene expression 
regulator of galactose-induced genes. Gal4 encodes for enzymes which convert galactose 
to glucose. In order to ensure that this chimeric DNA was replicated continuously, the 
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vector contained antibiotic resistance to Zeocin, which was present in the cell culture 
medium at all times. 37 
β-lactamase is an enzyme which is produced by some bacteria and causes 
resistance to β-lactam antibiotics.38 The β-lactam antibiotics contain a four-member ring 
with three carbon atoms and one nitrogen atom. The β-lactamase enzyme breaks the ring 
open, which deactivates the antibacterial properties. The second vector also contained 
antibiotic resistance to Hygromycin B, which was also present in the cell culture medium 
at all times.  
Culturing these cells in the presence of these 2 antibiotics ensured the 
transcription and translation of the VDR-LBD-Gal4-DBD and the availability of the 
reporter DNA bearing the bla gene (Figure 6). 
 
  
 
 
 
 
Figure 6: Binding of the first chimeric plasmid vector to the UAS of the second 
chimeric plasmid vector. 
 
 
 
Chapter 2.3: Background and Description of the Gene BLAzer FRET Assay 
This assay was used to detect the influence that CBIs have on the interference of 
transcription mediated by the VDR-LBD; therefore, cells were evaluated in the presence 
of calcitriol, which activated the VDR-LBD conformational change and allowed for the 
  VDR-LBD   Gal4-DBD 
  UAS Response Element   bla Gene 
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recruitment of coactivators. The binding of the Gal4-DBD from the first chimeric 
plasmid vector to the UAS response element of the second chimeric plasmid vector 
triggered the transcription of the bla gene, which ultimately resulted in the generation of 
β-lactamase enzyme.    
The expression of cellular β-lactamase was measured by the addition of a 
substrate (CCF4-AM) with the ability to create a FRET signal. CCF4-AM substrate has 
two2 fluorescent moieties, coumarin and fluorescein, which are linked by a β-lactam ring 
(Figure 7).4  
 
 
 
 
 
 
Figure 7: Structure of the CCF4-AM FRET substrate. 
 
 
 
FRET is made possible by the presence of two fluorescent scaffolds in close 
proximity, that is, they are linked together in one molecule. Fluorescence is best 
explained with the Jablonski diagram in Figure 8. 39 
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Figure 8: Jablonski diagram. An electron is excited by an energy source, and light is 
emitted when the electron returns to the ground state. This diagram shows possible routes 
that an excited electron can take when returning to the ground state. A rapid return to 
ground state results in fluorescence emission, and a slow return to ground state results in 
phosphorescence, after light crosses to the triplet state by intersystem crossing and 
undergoes internal conversion. 
 
Using light of a certain wavelength, which corresponds to the absorbance 
wavelength of the molecule, an electron is excited from the ground state to any one of the 
singlet states, in this case, to the second singlet state. As the electron drops back to the 
ground state, not all the energy is emitted as light, but some of the energy is lost, usually 
as vibrational energy or heat. As a result, the emission wavelength is shifted to a higher 
wavelength than the excitation wavelength. If relaxation occurs by intersystem crossing, 
the electron can enter the triplet state and emit the energy as phosphorescence. 40-42 
  
The FRET diagram 
and acceptor are present in close proximity, because the donor and acceptor have to be in 
close proximity in order for 
 
Figure 9: FRET diagram. The electron donor is excited to a single
transferred to an electron accep
spectra. 
 
The donor is excited to a singlet state
This transfer is not radiative. The emission spectrum of the donor and the excitation 
spectrum of the acceptor must
As described in the following 
r is the distance between the donor and the acceptor, which 
80 Å. 43 
 
(Figure 9) differs from the Jablonski diagram
significant energy transfer. 
t state,
tor through resonance transfer by overlapping emission 
, and energy is transferred to the acceptor. 
 overlap, or cause resonance, in order for FRET to occur. 
equation, the energy transfer is proportional to 
is typically around a
14 
, in that a donor 
 and energy is 
(1/r)6, where 
round 20-
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The CCF4-AM FRET substrate is a membrane-permeable, non-fluorescent 
substrate, which crosses the plasma membrane and enters the cell cytoplasm, where 
esterases hydrolyze the esters in the substrate into carboxylic acids, causing the substrate 
to become fluorescent (Figure 10). The carboxylate groups of the substrate are 
derivatized as esters, in order to ensure the high permeability needed to cross cell 
membranes. In the absence of β-lactamase activity, the substrate remains intact.4 
Excitation of the coumarin by 409 nm light results in FRET to fluorescein, which emits 
light at 530 nm (Figure 10).  
In the presence of β-lactamase activity, the CCF4-AM substrate is cleaved at the 
β-lactam ring, which interrupts energy transfer, causes the fluorophores to separate, and 
terminates the FRET signal. Under these conditions, the excitation of coumarin results in 
the emission of fluorescence at 460 nm (Figure 10).4  
 
 
 
 
 
 
 
Figure 10: In-cell FRET diagram. The substrate permeates though the cell membrane 
and is cleaved by esterases to form a highly fluorescent compound, CCF4. Cleavage by 
β-lactamase releases the fluorescent coumarin derivative. 
CCF4 
CCF4-AM 
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The expression of β-lactamase was quantified by measuring the ratio of the blue 
(460 nm) fluorescence to the green (530 nm) fluorescence.4 The CCF4-AM substrate 
works in conjunction with the Hek 293T cells, because the Hek 293T cells contain a β-
lactamase reporter gene system. CBI inhibition of the VDR-coactivator interaction 
created a FRET signal, and showed that the β-lactamase was not formed. The opposite 
was true of VDR agonists, which activated the VDR-LBD and resulted in the 
transcription of the β-lactamase gene, which produced β-lactamase. The production of β-
lactamase caused the substrate to be cleaved, and ultimately, a blue fluorescence 
emission.  
Quantification of β-lactamase was accomplished by detecting the increase in 
FRET caused by inhibiting the enzymatic cleavage of the β-lactam-containing substrate, 
which was added after an incubation ranging from 5 to 24 hours. The cleaved substrate 
concentration was quantified by measuring the fluorescence emission at 460 nm, and the 
uncleaved substrate concentration was quantified by measuring the fluorescence emission 
at 530 nm.  
 
Chapter 2.4: Gene BLAzer FRET Assay Methods 
The Hek 293T cells were passaged using the methods described later in this chapter and 
resuspended in assay media at a concentration of 20,000 cells per well. The assay media 
contained 500 mL of phenol red-free Dulbecco’s modified eagle medium (DMEM); 10 
mL of charcoal-stripped FBS; 5 mL of sodium pyruvate; 5 mL of non-essential amino 
acids; and 5 mL of penicillin and streptomycin. The cells were counted by pipetting 30 
µL of cell suspension onto a hepatocytometer, giving the concentration of cells per mL. 
17 
 
 
The assay was performed with 30 µL per well, giving a concentration of 666,666 cells per 
mL, which was adjusted to 660,000 cells per mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Hepatocytometer depiction. Approximately 30 µL of cell suspension was 
pipetted into this whole area. Cells were then counted in three separate red boxes and 
averaged. The volume of each of the red boxes was a 100 nL. Multiplication by 10,000 of 
the amount of cells counted gave the concentration of cells in cell per mL. 
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Matrigel solution was first pipetted into the 384-well black, clear bottom plate 
using a multi-channel pipette in the quantity of 30 µL, and the 384-well plate was 
incubated at 37°C and 5 percent carbon dioxide for 15 minutes, in order to allow the cells 
to attach to the plate. The Matrigel solution is described later in this chapter. Then, 30 µL 
of the cell suspension was pipetted into columns 1-23 of the same 384-well plate using a 
multi-channel pipette. Media only was pipetted into column 24 of the 384-well plate. The 
plate was incubated at 37°C and 5 percent CO2 for times ranging from 2 to 24 hours.   
The CBIs were transferred using a robotic pin tool transfer instrument, called the 
Tecan Freedom Evo liquid handler. This instrument allows for the transfer of 100 nL of 
liquid, which in this case, the liquid contained CBIs dissolved in DMSO. Controls for this 
assay were 1, 25-(OH)2D3 and LG 190178 (positives) and DMSO (negative). Two 
independent experiments were conducted in triplet or quadruplet for each of the Gene 
BLAzer assays.   
After the 384-well plate containing the cells was incubated for 2 to 24 hours, 8 µL 
of the FRET substrate was added to the wells for detection of the FRET signal using the 
Tecan Infinite M-1000 multi-label reader. The Tecan reader analyzed the excitation and 
emission of the blue and green fluorescence, and a ratio of the blue fluorescence to green 
fluorescence was determined.   
 
Chapter 2.5: Fluorescence Detection  
The excitation and emission of blue fluorescence were detected at 409 nm and 460 nm, 
respectively. The excitation and emission of green fluorescence were detected at 409 nm 
and 530 nm, respectively. The readings for the beginning assays were taken right after 
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centrifugation at 1 hour, 2 hours, 3 hours, and 4 hours after the addition of the FRET 
substrate. It was determined that the smallest standard deviation and highest signal 
window between the positive and negative controls were obtained after 3 hours of 
incubation at room temperature and in a dark environment. The fluorescence was read 
using the Tecan Infinite M-1000, which is a monochromator-based instrument.  
 The Tecan Infinite M-1000 spectrofluorimeter consists of the light source, the 
fluorescent top optics, the fluorescent bottom optics, and the fluorescence detector. The 
entire fluorescent optical system is illustrated in Figure 12.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Entire fluorescent optical system, which consists of the light source, 
the fluorescent top and bottom optics, and the fluorescence detection unit.  
 
 
The fluorescence optical path begins with the top light that contiunes from the 
light source to the top measurement head and to the photomultiplier tube (PMT). The 
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path of the fluorescent bottom light continues from the light source to the bottom 
measurement head, and to the PMT. 
The light source system has the following components: flash lamp, condenser, 
order-sorting filter wheel, excitation double monochromator, fiber optic bundle, and flash 
lamp monitor. The flash lamp uses a high-energy xenon arc discharge lamp, where the 
flash sparks across a small gap between two electrodes and the lamp bulb, which contains 
a high pressure xenon atmosphere. The benefits of using a xenon flash lamp are high 
intensity from the deep ultraviolet region to the near infrared region, a long lifetime, and 
the ability to be used for a variety of applications.  
The condenser focuses the light source onto the entrance slit of the excitation 
monochromator. A filter wheel is located between the condenser and the excitation 
monochromator and is set automatically, based on the programmed wavelength. The 
filter wheel contains wavelength-specific optical fibers, which are necessary to block 
undesired diffraction produced by the optical gratings (e.g. higher order energies). The 
excitation double monochromator is used to select desired wavelengths from the flash 
lamp spectrum in the range of 230 nm to 850 nm for fluorescence intensity.  
 A monochromator is an optical instrument that enables any wavelength to be 
selected from a defined optical spectrum, which consists of an entrance slit, a dispersive 
element, and an exit slit. The dispersive element diffracts the light and projects it onto the 
exit slit. A dispersive element can be realized by using a glass prism or an diffraction 
grating, which the later is used in the Tecan Infinite M-1000. Rotating the optical grating 
around its vertical axis moves the spectrum across the exit slit, and only a small part of 
the spectrum, or bandpass, passes through the exit slit. That means that when the 
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monochromator entrance slit is illuminated with white light, only light with a specific 
wavelength, or monochromatic light, passes through the exit slit. The wavelength of this 
light is set by the rotation angle of the optical grating. The bandwidth is set by the width 
of the exit slit.  
Since monochromators only block undesired wavelengths to 103, a second 
monochromator is needed in order to detect fluorescent light, because the detectable 
fluorescent light is much weaker than the excitation light. The second monochromator is 
connected in series, that is, the exit slit of the first monochromator acts as the entrance slit 
of the second monochromator, which allows for blocking to a factor of 106. In this 
instrument, a double monochromator is on both the excitation and emission side.  
 The fiber optic bundle guides the light from the exit slit of the excitation 
monochromator, either to the top measuring optics or the bottom measuring optics. The 
bottom fluorescent optical system, which is identical to the top fluorescent optical 
system, is illustrated in Figure 13.  
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Figure 13: Schematic diagram of spectrofluorimeter showing the optics for 
reading both above and below the microplate. Fluorescence optics used for top 
and bottom reading of fluorescence intensity measurement. The right-hand side is 
an enlargement of the bottom fluorescence measurement, which is similar to the 
top fluorescence measurement. 
 
 
The lower end of each fiber bundle acts as a color-specific light source. In both 
cases, a small portion of the light is guided to the flash lamp monitor diode. The flash 
lamp monitor is a silicon photodiode that takes single flash light variations into account 
and compensates for them. 
The fluorescence fiber bundle that is plugged into the top and bottom measuring 
head contains both excitation and emission fibers. The emission fibers guide the 
fluorescent light to the emission monochromator head, where a lens system focuses the 
light onto the entrance slit of the emission monochromator. 
The fluorescence detection system is used for measuring both fluorescence from 
above and fluorescence from below the microplate wells. The fluorescent light is focused 
onto the entrance slit of the emission monochromator. After passing through the 
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monochromator, the light passes through the filter wheel and is focused on the detector 
(PMT).  
 The emission monochromator is used to select any wavelength of fluorescent 
signal. It acts like an adjustable filter in wavelength and bandwidth to discriminate scatter 
of excitation light and non-specific fluorescence. The filter wheel contains wavelength 
specific optical fibers, which are necessary to block undesired diffraction produced by the 
optical gratings. The PMT is used for the detection of fluorescent low light levels, and 
electronic circuitry uses analog to digital conversion of PMT output current.     
The Z-position of the fluorescence top optics helps to maximize the signal to 
noise ratio, as light is refracted at the sample’s liquid surface. The fluorescence intensity 
lens system of both the top and bottom optics is designed to focus the excitation light at 
the exit side of the bundle, which acts as a color-specific light source, into the sample. 
The lens also collects the fluorescent light and focuses it back onto the fluorescence fiber 
bundle. The objective lenses are made from fused silica, which provides high ultraviolet 
transmission and eliminates most auto-fluorescence.  
In summary, the flash light is focused by the condenser on the entrance slit of the 
excitation monochromator. The wavelength and bandwidth of the excitation light are 
selected within the monochromator. After passing through the monochromator, the 
excitation light is coupled into a fiber bundle guiding the light to the top or bottom 
measuring heads. The light is then focused into the sample by the top or bottom lens 
system. The fluorescent emission light is collected by the top or bottom lens system 
again, coupled into the fluorescence fibers bundle, and guided to the detection system. 
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The blue fluorescence emission, and then the green fluorescence emission, of the 
assay wells that were quantified by using the Tecan Infinite M-1000 instrument were 
displayed in an Excel spreadsheet across the row of the 384-well plate.  
This raw data was applied to another spreadsheet in order to reorganize the data, 
to subtract the average of the background of the assay media from the wells, to determine 
the trend in blue fluorescence, to determine the trend in green fluorescence, to determine 
the ratio of blue to green fluorescence, to determine the averages of the positive and 
negative controls, to determine the standard deviation of the positive and negative 
controls and to determine the Z prime value as shown in Figure 14. The data was 
arranged into columns of descending concentrations for each CBI, and to group multiple 
plates for the same batch of cells in triplet or quadruplet.  
The average values (n =3 or 4) were analyzed with Graph Pad Prism 5. Any data points 
that fell outside of three times the standard deviation were discarded. The two-
dimensional graphs consisted of the ratio of blue to green fluorescence on the y-axis and 
the logarithm of the concentration of agonist or CBI on the x-axis. The best-fit non-linear 
regression was color-coded to match the legend for that molecule. The compounds that fit 
the sigmoidal graph shape were determined to be the most promising compounds, and an 
IC50 value for each of these sigmoidal graphs was determined. 
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Figure 14: Z prime calculation. The Z prime value indicates the correlation of the 
experimental data. Z prime values from 0.50 to 1.0 indicate useful data sets.  
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Chapter 2.6: Hek 293T Cell Culture Methods 
A 1 mL tube with commercially available Hek 293T cells was first thawed and pipetted 
into 10 mL of growth media. The growth and thawing media contained 500 mL of phenol 
red DMEM with Glutamax (L-glutamate); 50 mL of heat-inactivated and dialyzed FBS; 5 
mL of 0.1 mM non-essential amino acids (glycine (750mg/L), L-alanine (890 mg/L), L-
asparagine (1320 mg/L), L-aspartic acid (1330 mg/L), L-glutamic acid (1470 mg/L), L-
proline (1150 mg/L), and L-serine (1050 mg/L)); 5 mL of HEPES buffer at pH 7.3, which 
maintains a physiological pH, despite carbon dioxide changes from respiration; and 5 mL 
of 100 µg/mL Penicillin and Streptomycin. The cell suspension was centrifuged at 1,000 
rpm for 2 minutes. The supernatant was aspirated from the top, the cells were 
resuspended in 1 mL of media, and the cells were introduced into a tissue cell culture 
flask, which had been pre-coated with 3 mL of Matrigel matrix solution and contained 14 
mL of growth media.  
The Matrigel matrix solution contained 100 mL of phenol red-free DMEM and 
250 µL of Matrigel concentrate and was used to coat the bottom of the tissue cell culture 
flasks and the 384-well plates prior to introducing the cells to the flasks and to the plates. 
Matrigel is a protein that is extracted from moose sarcoma cells and simulates the cell 
growth environment; therefore, Matrigel facilitates the attachment of the cells to the 
bottom of the tissue culture flasks. The 3 mL of Matrigel that had been added to the 
bottom of the tissue culture flasks coated the entire bottom surface of the flasks. The 
flasks with the Matrigel solution were incubated at 37°C and 5 percent carbon dioxide for 
15 minutes. The Matrigel solution was aspirated, and the 14 mL of growth media was 
added to the flasks.  
  
The amount of Zeocin added 
changed to 15 µL, which corresponds to a final concentration of 
to 100 µg/mL. The same con
directly to the culture flasks
concentration of 80 µg/mL, 
added to the tissue culture flasks each time the cells were propagated
Hygromycin B is an
Streptomyces hygroscopicus
affecting mRNA translation, which is achieved by inducing the misreading of aminoacyl
tRNA through the distortion of the ribosomal 
Zeocin is a copper
Streptomyces verticillus (Figure 15B)
cation is reduced from Cu
Removing the copper cation from the 
is activated, it binds to DNA and cleaves it, causing cell death.
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The cells were cultured to 70 to 95 percent confluency in the 15 mL solution of 
growth media and antibiotics from 2 to 5 days. Once the cells reached an appropriate 
confluency, the cells were washed with 10 mL of PBS without calcium ions and detached 
from the tissue culture flasks using 3 mL of 0.5 percent trypsin.  
Trypsin is a protease enzyme which degrades proteins by hydrolysis and has an 
optimum working pH of 7 to 9. Trypsin is derived from trypsinogen in the pancreas by 
removing a terminal peptide from the trypsinogen. It is a highly discriminating protease, 
because it only cleaves amide and ester bonds at the carboxyl terminal side of arginines 
and lysines. Trypsin is inhibited by organophosphorous compounds which target serine in 
the active site of the enzyme. FBS contains a natural inhibitor of trypsin.   
The cells were incubated for 3 to 5 minutes with the trypsin at 37°C and 5 percent 
carbon dioxide. The cell suspension was mixed by pipette and added to 7 mL of growth 
media in a conical tube, followed by 5 minutes of centrifugation at 1,000 rpm. The 
growth media was aspirated from the top of the cells, pelleted on the bottom of the 
conical tube, resuspended in 3 mL growth media, and 1 mL of this cell suspension was 
introduced to each new culture flask.  
 
Chapter 2.7: Summary of the Results of the Gene BLAzer Assay 
As discussed previously, Hek 293T cells were drugged with calcitriol ligand and CBIs, in 
order to determine the CBI’s ability to inhibit VDR-mediated transcription using the 
described Gene Blazer assay. The summary of the structures of CBIs tested and their 
activities are compiled in Table 7 in Appendix A. 
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Figures 16 through 26 and Figure 28 represent the dose-response activity of all 
CBIs investigated. The graphs show the ratio of blue to green fluorescence, the blue 
fluorescent signal, and the green fluorescent signal for each compound. The reduced ratio 
of blue to green fluorescence is an indicator of the ability of CBIs to inhibit the 
transcription of VDR. The amount of blue fluorescent signal is directly related to the 
transcription of the lactamase gene, and consequently, to the activation of VDR. A blue 
fluorescent signal is an indication that the cleavage of the Gene BLAzer fluorescent 
substrate at the β-lactam ring by the β-lactamase enzyme occurs and that blue 
fluorescence is emitted by the Gene BLAzer fluorescent substrate.  
The amount of green fluorescent signal is proportional to the amount of 
transcriptional inhibition of the lactamase gene mediated by VDR. The green fluorescent 
signal is an indication that no cleavage of the Gene BLAzer fluorescent substrate at the β-
lactam ring by the β-lactamase enzyme occurs. The inhibition of the cleavage of the Gene 
BLAzer fluorescent substrate shows the ability of the CBIs to inhibit the transcription of 
VDR. Active CBIs will inhibit the VDR-mediated transcription of the lactamase gene, 
resulting in a lower blue fluorescent signal and a higher green fluorescent signal, as the 
concentration increases. The decrease in green fluorescent signal also shows the toxicity 
of the small molecules. Both signals should be inversely proportional; thus, giving a 
robust additive signal when divided, as described in the introduction. The IC50 values 
were determined using the following non-linear regression equation. 
Y=Bottom + (Top-Bottom)/(1+10(Log IC50-X)*Hill Slope).  
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The IC50 value is half of the maximum inhibitory concentration that measures the 
effectiveness of a compound in inhibiting a biological function, in this case, transcription 
inhibition.  
 
 
Chapter 2.8: Detailed Results and Figures of the Gene BLAzer Assay 
 
A 
 
B 
 
C 
Figure 16: Inhibition of VDR-mediated transcription of compounds F1387-0020, F1387-
0036, F1217-0092, F0910-7407, and F0743-0032. 
 
 
 
Compounds F1387-0020, F1387-0036, F1217-0092, F0910-7407, and F0743-
0032 all decreased in blue fluorescence after 3 hours at the highest concentration tested 
(Figure 16A). The activity can be interpreted that transcription increased with decreasing 
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concentration, thereby giving an increased blue signal as the graph goes from a higher to 
a lower concentration, and giving a decreased green signal as the graph goes from a 
higher concentration to a lower concentration. Compounds F0910-7407, F0743-0032, and 
F1217-0092 were less active than compounds F1387-0020 and F1387-0036. The IC50 
values of compounds F1387-0020 and F1387-0036 were 12.3 μM and 12.4 μM, 
respectively (Figure 16C). In addition, compounds F1387-0020 and F1387-0036 were 
slightly more toxic than the other compounds in this compound set at higher 
concentrations, indicated by the decrease in green fluorescent signal (Figure 16B).  
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Figure 17: Inhibition of VDR-mediated transcription of compounds F0842-0039, F1387-
0021, F1387-0022, F1387-0034, and F1420-1568. 
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Compounds F0842-0039, F1387-0021, F1387-0022, F1387-0034, and F1420-
1568 all decreased in blue fluorescence after 3 hours at the highest concentration tested, 
which is equivalent to a decreased amount of β-lactamase transcribed by VDR (Figure 
17A). Interestingly, only compounds F0842-0039, F1387-0022, and F1387-0034 
exhibited an increased green fluorescent signal at higher concentrations, resulting from 
uncleaved substrate (Figure 17B). The most active compound of the 5 compounds in this 
compound set was compound F0842-0039, with an approximate IC50 value of 8 µM. 
Compound F0842-0039 exhibited a decrease in the blue fluorescent signal and an 
increase in the green fluorescent signal (Figure 17C). Additionally, signs of high toxicity 
were observed at the highest concentration of 62.5 µM for all compounds, except 
compound F1420-1568, which is depicted by the decreased green fluorescent signal at 
that concentration (Figure 17B). 
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Figure 18: Inhibition of VDR-mediated transcription of compounds F1387-0028, F1298-
0533, F1298-0551, F1298-0074, and F1298-0581. 
 
 
 
Compounds F1387-0028, F1298-0533, F1298-0551, F1298-0074, and F1298-
0581 all decreased in blue fluorescence after 3 hours at higher concentrations (Figure 
18A). Only compounds F1387-0028, F1298-0074, and F1298-0581 exhibited an 
increased green fluorescent signal at the highest concentrations tested (Figure 18B). 
Because only the highest concentration showed a change of signal for all five 
compounds, it was not possible to calculate reliable IC50 values for these compounds.  
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Figure 19: Inhibition of VDR-mediated transcription of compounds F1298-0621, F1298-
0587, and F1298-0522. 
 
 
 
Among the 3 compounds tested in this compound set, F1298-0621, F1298-0587, 
and F1298-0522, only compound F1298-0587 decreased in blue fluorescence after 3 
hours at higher concentrations (Figure 19A). Additionally, two experiments with vehicle 
DMSO were added as a negative control. Only compound F1298-0587 showed an 
increased green fluorescent signal at a concentration of 21 µM, which decreased at the 
highest concentration tested. It can be concluded that only compound F1298-0587 was 
able to inhibit VDR-mediated transcription, because it had an IC50 value of 17.6 µM and 
was toxic at 62.5 µM (Figure 19C). 
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Figure 20: Inhibition of VDR-mediated transcription of compounds D093-0045, D093-
0086, and F1298-0025. 
 
 
 
Compounds D093-0045 and D093-0086 decreased in blue fluorescence after 3 
hours at higher concentrations (Figure 20A). Additionally, two experiments with vehicle 
DMSO were added as a negative control. Although there was a decrease in blue 
fluorescent signal for compound D093-0086, it can be concluded that it was not an active 
compound. The IC50 values for compounds D093-0045 and D093-0086 were 5.8 µM and 
6.6 µM, respectively (Figure 20C).   
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Figure 21: Inhibition of VDR-mediated transcription of compounds WL052410D, 
WL052510D, WL052510F, and WL052510H. 
 
 
 
Compounds WL052410D, WL052510D, WL052510F, and WL052510H, which 
were all based on the same chemical scaffold, decreased in blue fluorescence after 3 
hours at higher concentrations (Figure 21A). Compounds WL052510D and WL052510H 
were more active than compounds WL052410D and WL052510F. Consequently, for 
compounds WL052510D and WL052510H, an increased green fluorescent signal was 
observed at 3.3 µM, which indicated inhibition of VDR-mediated transcription (Figure 
21B). Toxicity at the highest concentrations was observed for all compounds. The IC50 
values for all 5 compounds ranged from 9.1 to 12.4 µM (Figure 21C).   
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Figure 22: Inhibition of VDR-mediated transcription of compounds WL052510K and 
WL052510M. 
 
 
 
From the 2 compounds tested in this compound set, only compound WL052510M 
exhibited a decrease in blue fluorescence after 3 hours at the higher concentrations 
(Figure 22A). As expected, the green fluorescent signal of compound WL052510M 
increased with higher concentration (Figure 22B). The IC50 value for compound 
WL052510M was 11.4 µM, and compound WL052510K was not an active compound 
(Figure 22C). 
Blue to Green Fluorescence Ratio at 3 Hours
0.0 0.5 1.0 1.5
0.0
0.5
1.0
WL052510K
WL052510M
IC50 (WL052510M)= 11.4 µM
log [Antagonist] (uM)
B
lu
e/
G
re
en
 
Fl
u
o
re
sc
en
ce
Blue Fluorescence at 3 Hours
0.0 0.5 1.0 1.5
0
5000
10000
15000
20000
log [Antagonist] (uM)
B
lu
e 
Fl
u
o
re
sc
en
ce
Green Fluorescence at 3 Hours
0.0 0.5 1.0 1.5
0
5000
10000
15000
20000
25000
log [Antagonist] (uM)
G
re
en
 
Fl
u
o
re
sc
en
ce
37 
 
 
A 
 
B 
 
C 
 
Figure 23: Inhibition of VDR-mediated transcription of compounds WL052410G, 
WL052410K, WL052410N, and WL060110G. 
 
 
 
Compounds WL052410G, WL052410K, WL052410N, and WL060110G all 
decreased in blue fluorescence after 3 hours at higher concentrations (Figure 23A). The 
green fluorescent signal was significantly increased for compounds WL052410K and 
WL060110G at a concentration of 3.3 µM, but reduced at 10 µM, due to toxicity. 
Compounds WL052410G and WL052410N showed no increase at all in green 
fluorescent signal, which is most likely due to a very small window between activity and 
toxicity; therefore, no IC50 values are given for these compounds. However, the IC50 
values of compounds WL052410N and WL060110G were 7.2 µM and 8.8 µM, 
respectively (Figure 23C).   
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Figure 24: Inhibition of VDR-mediated transcription of compounds WL060110H, 
WL040710D, and WL042210G. 
 
 
 
Compounds WL060110H, WL040710D, and WL042210G all decreased in blue 
fluorescence after 3 hours at higher concentrations (Figure 24A). The green fluorescent 
signal was increased for compound WL040710D (Figure 24B). It can be concluded that 
both compounds WL040710D and WL042210G were very active, with IC50 values of 
11.2 µM and 12.0 µM, respectively (Figure 24C).   
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Figure 25: Inhibition of VDR-mediated transcription of compounds WL061410C, 
WL042210D, WL060310C, and WL061410K. 
 
 
 
Among all of the compounds tested in this compound set, only compounds 
WL061410C, WL060310C, and WL061410K decreased in blue fluorescence after 3 
hours at the highest concentration tested (Figure 25A). None of the compounds showed 
an increase in green fluorescent signal, but rather, a decrease in green fluorescent signal; 
therefore, accurate IC50 values for these four compounds were unable to be determined 
(Figure 25B).  
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Figure 26: Inhibition of VDR-mediated transcription of compounds WL042210G, 
WL042210K, and WL060110G. 
 
 
 
Compounds WL042210G, WL042210K, and WL060110G all decreased in blue 
fluorescence after 3 hours at the higher concentrations (Figure 26A). Accordingly, the 
green fluorescent signal increased for all compounds, except for the highest concentration 
of 25 µM; thus, all 3 compounds were active, with IC50 values of 8.1 µM, 10.4 µM, and 
4.8 µM, respectively (Figures 26B and 26C).   
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Another compound identified by HTS as a potential CBI of VDR was compound 
GW 0742 (Figure 27). The inhibition of transcription mediated by VDR was determined 
twice in quadruplet, as depicted in Figure 28.  
 
 
 
 
 
 
 
 
Figure 27: Structure of compound GW 0742. 
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Figure 28: Inhibition of VDR-mediated transcription of compound GW 0742. 
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The 2 measurements for compound GW0742 show reproducible data. The blue 
fluorescent signal decreased at higher concentrations after 3 hours, whereas the green 
fluorescent signal was the highest at the highest concentration tested at 3 hours, as seen in 
Figures 28A and 28C. Both results show that compound GW 0742 inhibited VDR-
mediated transcription, with IC50 values between 25.1 µM and 27.3 µM.  
Compound GW 0742 was introduced by GlaxoSmithKline in 2003 as a highly 
selective agonist for PPARδ.44 Since then, compound GW 0742 has been investigated in 
cell-based assays and in vivo, in order to understand the role of PPARδ in hypertension,45, 
46
 diabetes,47, 48 inflammation,49, 50 obesity,51 and cancer.52-54 Interestingly, PPAR agonists 
have been shown to inhibit the transcription of the VDR target gene, CYP24A1, in the 
presence of 1, 25-(OH)2D3;55 therefore, compound GW 0742 was tested for transcription 
inhibition and cytotoxicity. It was determined that at micromolar concentrations, 
compound GW 0742 behaved as an antagonist of VDR.56 
 
Chapter 2.9: Discussion of the Results of the Gene BLAzer Assay 
In total, 39 compounds were investigated with respect to their ability to inhibit 
transcription mediated by VDR. Interestingly, many different scaffolds were able to 
modulate gene regulation; however, high toxicity was a concern with some of these 
molecules. The class of 3-indolyl methanamines (compounds F0842-0039, F1217-0092, 
F1387-0028, F1387-0021, F1387-0036, F0743-0032, F1387-0020, F1387-0034, and 
F1387-0022) was identified as the superior class of irreversible inhibitors of the VDR-
coactivator interaction. These compounds were shown to inhibit this interaction in Hek 
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293T cells, which led to inhibition of transcription. The results presented previously in 
this chapter are published in Nandhikonda et al.29  
 The 3-indolyl methanamine class varied in aromatic substituents. Compound 
F0842-0039 had a phenol group; compound F1217-0092 had a para toluene group; 
compound F1387-0028 had a meta anisole group; compound F1387-0021 had a meta 
bromobenzene group; compound F1387-0036 had a para bromobenzene group; 
compound F0743-0032 had a para fluorobenzene group; compound F1387-0020 had a 
para xylene group; compound F1387-0034 had a meta chlorobenzene group; and 
compound F1387-0022 had a meta fluorobenzene group.  
 Of these compounds, compound F0842-0039, which had a phenol group and an 
IC50 value of 8.6 µM; compound F1387-0036, which had a para bromobenzene group and 
an IC50 value of 12.4 µM; and compound F1387-0020, which had a para xylene group and 
an IC50 value of 12.3 µM, were the most active. The rest of the compounds in this class 
showed little to no transcriptional inhibition. Of the remaining commercially available 
compounds, only compound F1298-0587 and compound D093-0045 had only a slight 
potential for transcription inhibition. 
 Of the compounds synthesized from the 3-indoyl methanamines, compounds 
WL052410D (30c), which had an anisole group and an IC50 value of 12.4 µM; 
WL052510D (30a), which had a benzene group and an IC50 value of 10.8 µM; 
WL052510F (30d), which had a toluene group and an IC50 value of 12.2 µM; 
WL052510H (30b), which had a chlorobenzene group and an IC50 value of 9.1 µM; 
WL052510M (30f), which had a nitrobenzene group and an IC50 value of 11.4 µM; 
WL052410K (31c), which had a para methoxybenzene group and an IC50 value of 7.2 
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µM; WL060110G (31d), which had a toluene group and an IC50 value of 8.8 µM; 
WL040710D (31a), which had a benzene group and an IC50 value of 11.2 µM; 
WL042210G (31h), which had an ortho methoxybenzene group and an IC50 value of 12.0 
µM; WL042210K (30h), which had a napthylbenzene group and an IC50 value of 10.5 
µM; and WL052410G (31b), which had a chlorobenzene group and an IC50 value of 4.9 
µM, were the most active compounds. 
 When considering small molecules for therapeutic use, the compounds that are 
most active and are partially toxic have the greatest potential. Of the above listed 
compounds, compound WL042210K (30h), which had a napthylbenzene group and an 
IC50 value of 10.5 µM; compound WL052410G (31b), which had a chlorobenzene group 
and an IC50 value of 4.9 µM; compound WL052410K (31c), which had a para 
methoxybenzene group and an IC50 value of 7.2 µM; and compound WL060110G (31d), 
which had a toluene group and an IC50 value of 8.8 µM, have the greatest potential for 
therapeutic uses. The characteristic that all of these compounds have in common, besides 
being 3-indolyl methanamines, is that they have electron-donating aryl substituents or 
ortho, para directing groups, such as chlorine, which appears to be effective in inhibiting 
VDR-mediated transcription. 
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Chapter 3: Cell Titer-Glo Luciferase Assay 
 
 
 
Chapter 3.1: Background and Description of the Cell Titer-Glo Luciferase Assay 
 
The cytotoxicity of CBIs was determined by luminescence using Cell Titer-Glo reagent 
(Promega). This reagent determines the number of viable cells in a well-based assay by 
the quantification of adenosine triphosphate (ATP), which is an indicator of metabolically 
active cells. The Cell Titer-Glo reagent contains a surfactant, which causes cell lysis for 
ATP liberation, and through an enzymatic reaction, generates a luminescent signal that is 
proportional to the amount of ATP liberated. The thermally stable luciferase enzyme used 
in this assay produces the stable luminescent signal, while the reagent inhibits enzymes 
released during cell lysis, such as ATPases, which will interfere with obtaining an 
accurate ATP measurement.57 In summary, the Cell Titer-Glo reagent lyses cell 
membranes to release ATP, inhibits endogenous ATPases, and provides the purified 
luciferin and luciferase necessary to measure ATP using a bioluminescent reaction. The 
luciferase used in this assay is based on the gene from the firefly, Photuris pennsylvanica.   
Luciferase is a great detection enzyme, because it is absent in mammals, and it 
has a luminescent quality which can be quantified by a luminescent reader. ATP is a 
required cofactor of the luciferase reaction. The luciferase enzyme acts on luciferin in the 
presence of magnesium cations and oxygen, and releases energy in the form of 
luminescence, that is, light is produced by the oxidation of luciferin (Figure 29).  
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Luciferin and ATP combine to form adenyl
and magnesium cations (Figure 30
oxyluciferin, carbon dioxide, and water, while the energy released is in the form of 
luminescence. The luminescent signal that is produced is propor
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Figure 30: The interaction between ATP and luciferin in the presence of luciferase, 
magnesium cations, and oxygen. 
 
 
 
Chapter 3.2: Luminescence 
Luminescence is a term applied to all forms of cool light, or light that is emitted by 
sources other than a hot and incandescent source, such as chemical energy or U.V. 
radiation. Generally, luminescence is caused by electrons falling from excited states to 
less excited states. The types of luminescence are usually named after the source of 
energy that excites the electron. For example, chemiluminescence is mainly produced by 
oxidation reactions at low temperatures, and bioluminescence is an enzymatic reaction 
that is produced by living organisms by some form of chemiluminescence. 
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Bioluminescence is unique in that the excitation of the electrons comes from a 
reaction inside the living system, rather than from some external source; however, the 
distinguishing terms used for the different types of luminescence are used for 
convenience, because luminescent phenomena have the same mode of excitation, 
regardless of the source.  
There are two classifications of luminescence. Fluorescent luminescence stops 
shortly after the excitation process ceases and has an afterglow duration that is 
temperature-independent, whereas phosphorescent luminescence phosphorescence also 
continues after the excitation process ends but the emission lifetime is of much longer 
duration. Phosphoresence produces and afterglow with a duration that becomes 
increasingly shorter with increasing temperature. .    
 
Chapter 3.3: Luminescence Detection 
To detect the luminescent signal, the luminometer, illustrated in Figure 31, uses the single 
photon counting measurement technique, which is based on a photomultiplier tube 
(PMT). The luminescence system consists of the following parts: luminescence fiber 
bundle, filter wheel, and PMT detector. The luminescence fiber bundle guides the light 
from the sample, to the filter wheel, and finally to the detector.  
 The filter wheel has six filter positions better isolate the analytical signal. The 
photon counting module (PCM) is designed to read chemi- and bioluminescence and 
contains a channel photomultiplier, which provides luminescence measurement with 
strong variations in light levels. The PCM also provides high sensitivity and low noise to 
allow luminescence detection at very low light levels. 
49 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Luminometer detection system. 
 
 
 
The Z-position of the luminescence fiber bundle helps to maximize the signal to 
noise ratio and minimize cross-talk, as light is refracted by the sample’s liquid surface. 
The luminescence fiber bundle guides the light from the sample to the PMT detector. 
Luminescence is read from the top of the well and collects as much light as possible, in 
order to maximize the luminescent signal. “Cross-talk” is also minimized by the 
neighboring wells not receiving substantial amounts of light from other neighboring 
wells.  
 
Chapter 3.4: The Cell Titer-Glo Luciferase Assay  
Hek 293T cells were also used for this assay and were cultured, plated, and drugged in the 
same manner as described in the “Cell Culture and Gene BLAzer Assay” chapter. The 
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Gene BLAzer assay was completed first, followed by the addition of the Cell Titer-Glo 
reagent. Controls for cell viability were 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-
one59 (CBT-1; 100 µM in DMSO, positive control, toxic) and 1, 25-(OH)2D3 or LG 
19017860 (negative control, not toxic). Two independent experiments were conducted in 
triplet or quadruplet for each of the Cell Titer-Glo luminescence assays performed.    
To perform the luciferase assay, 30 µL of the Cell Titer-Glo reagent was added to 
each well of the 384-well plate that contained the cells, the positive and negative controls, 
and the assay media, using a multi-channel pipette. The plate was centrifuged for 2 
minutes at 1,000 rpm and allowed to sit for 15 to 20 minutes. The Tecan Infinite M-1000 
multi-label reader was used to measure the amount of luminescence generated from each 
well.  
The 384-well clear bottom plate was read with and without a white bottom sticker 
to compare the influence of escaping light through the bottom of the plate. Surprisingly, it 
was discovered that both experiments were the same quality, which was quantified by the 
Z prime factor (Figure 32). Table 1 demonstrates an example of an experiment with 
compound GW 0742 from exactly identical experimental conditions. These results were 
consistently observed after recording both observations. 
Additionally, it was determined that this assay could be multi-plexed with the 
Gene BLAzer assay for the same reason that the signals from each of the readings of the 
non-multi-plexed and multi-plexed signals were determined; thus, discovering a time-
saving and cost-saving shortcut (Table 1).  
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Figure 32: Z prime calculation. The Z prime value indicates the correlation of the 
experimental data. Z prime values from 0.50 to 1.0 indicate useful data sets.  
 
 
Compound Set With Sticker Z’ Value 
Without Sticker 
Z’ Value 
Not Multi-Plexed 
Z’ Value 
Multi-Plexed Z’ 
Value 
GW 0742 
(Plate UWM 
6515) 
0.911306 0.911340 0.911306 N/A 
GW 0742 
(Plate UWM 
6517) 
0.218768 0.373101 N/A 0.218768 
GW 0742 
(Plate UWM 
6519) 
0.999436 0.997010 N/A 0.999436 
GW 0742 
(Plate UWM 
6521) 
0.994719 0.996952 N/A 0.996952 
 
Table 1: Comparison of the Z prime values of 384-well plates containing compound GW 
0742, which were run with and without a bottom sticker and of 384-well plates that were 
not multi-plexed with the Gene BLAzer assay and that were multi-plexed with the Gene 
BLAzer assay. 
 
 
  
The luminescence readings of the wells were displayed in an Excel spreadsheet 
across the row of the 384-well plate. The average of the background of the assay media 
from the wells was subtracted from the raw data. The averages of the positive and 
negative controls were used to determine the standard deviation of the positive and 
negative controls and to determine the Z prime values of the data.   
The arranged triplet or quadruplet luminescence values were graphed using Graph 
Pad Prism 5. Any data points that fell outside of three times the standard deviation were 
discarded. The two-dimensional graphs consisted of the crude or normalized 
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luminescence values on the y-axis and the logarithm of the concentration of agonist or 
CBI on the x-axis (Figures 33 through 43 and Figure 45). The data were fit to a sigmoidal 
curve of variable slope.   
 
Chapter 3.5: Summary of the Results of the Cell Titer-Glo Luciferase Assay 
As discussed previously, Hek 293T cells were drugged with calcitriol ligand and CBIs to 
determine the CBI’s ability to inhibit VDR-mediated transcription using the previously 
described GeneBLAzer assay. The Cell Titer-Glo luciferase assay was used to determine 
the toxicity of the CBIs in Hek 293T cells, by measuring the chemiluminescent signal 
released by a luciferase-mediated reaction, which quantifies the amount of ATP in living 
cells.  
The following figures represent the crude luminescence signal, as well as the 
normalized data for each compound. The amount of luminescent signal is proportional to 
the amount of ATP emitted from the living cells. The higher the luminescent signal the 
more ATP that is present, which is indicative of a higher amount of metabolically active 
cells.  
The LD50 values are given for the most toxic compounds, which were calculated 
by the following non-linear regression equation. 
Y=Bottom + (Top-Bottom)/(1+10(Log IC50-X)*Hill Slope).   
The LD50 value is half of the maximum lethal dosage, which measures the 
effectiveness of CBI toxicity. For weakly toxic compounds, the percentage of non-living 
cells is given for the highest concentration tested.  
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Figures 33 through 43 and Figure 45 show the results of the Cell Titer-Glo 
luminescence cytotoxicity assay. The luminescent signal in all of these figures is 
equivalent to the amount of ATP released from living cells. The normalized data in all of 
these figures uses CBT-1, which is the same toxic compound in high concentration as a 
positive control, and 1, 25-(OH)2D3 or LG 190178 as the negative control. The positive 
and negative controls allow for the calculation of the percent toxicity. The degree of 
toxicity was quantified by the LD50 values, which are given for the most toxic 
compounds.  
 
Chapter 3.6: Detailed Results and Figures of the Cell Titer-Glo Luciferase Assay 
 
  A 
 
   B 
Figure 33: Toxicity of compounds F1387-0020, F1387-0036, F1217-0092, F0910-7407, 
and F0743-0032. 
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Compounds F1387-0020, F1387-0036, F1217-0092, F0910-7407, and F0743-
0032 all decreased in the crude luminescent signal after 3 hours at higher concentrations 
(Figure 33A). It can be interpreted that the compounds tested had varying degrees of 
toxicity at higher concentrations, because the luminescent signal was equivalent to the 
amount of ATP released from living cells. The normalized data using a toxic compound 
(CBT-1) in high concentration as a positive control, and 1, 25-(OH)2D3, as a negative 
control, allowed for the calculation of the percent toxicity given in Figure 33B. 
Compound F1387-0020 was the most toxic compound in this compound set, 
followed by compounds F1387-0036, F1217-0092, F0910-7407, and F0743-0032. The 
insufficient data for the saturated values, or the higher concentrations, for compounds 
F1217-0092, F0910-7407, and F0743-0032 resulted in the absence of LD50 values for 
these compounds; however, compound F1387-0020 had an accurate LD50 value of 11.7 ± 
3.5 µM, whereas compound F1387-0036 had an LD50 value of 21.5 ± 7.1 µM.  
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Figure 34: Toxicity of compounds F0842-0039, F1387-0021, F1387-0022, F1387-0034, 
and F1420-1568. 
 
 
 
Compounds F0842-0039, F1387-0021, F1387-0022, F1387-0034, and F1420-
1568 all decreased in the crude luminescent signal after 3 hours at higher concentrations 
(Figure 34A). The normalized data, depicted in Figure 34B, was based on the positive 
and negative controls in the same plate. The activity can be interpreted that compounds 
F0842-0039, F1387-0021, and F1387-0034 were toxic, and compounds F1387-0022 and 
F1420-1568 were somewhat toxic at the highest concentration tested. This interpretation 
can be made, because the luminescent signal decreased sharply for all of the compounds 
at this concentration, but compounds F0842-0039, F1387-0021, and F1387-0034 had the 
sharpest decrease (Figure 34A). In the normalized graph, the signal increased more 
sharply for compounds F0842-0039, F1387-0021, and F1387-0034, because the graph 
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was indicative of the percent toxicity at varying concentrations (Figure 34B). No LD50 
values could be calculated for any of these compounds, because of insufficient data for 
higher compound concentrations. 
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Figure 35: Toxicity of compounds F1387-0028, F1298-0533, F1298-0551, F1298-0074, 
and F1298-0581. 
 
 
Compounds F1387-0028, F1298-0074, and F1298-0581 all decreased in the crude 
luminescent signal after 3 hours at the higher concentrations, whereas compounds F1298-
0533 and F1298-0551 showed no signal change (Figure 35A). The activity can be 
interpreted that compounds F1298-0074 and F1298-0581 were toxic, compound F1387-
0028 was somewhat toxic, and compounds F1298-0533 and F1298-0551 were not toxic 
at the highest concentration tested. This interpretation can be made, because the 
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luminescent signal decreased sharply for compounds F1298-0074 and F1298-0581, 
somewhat sharply for compound F1387-0028, and not at all for compounds F1298-0533 
and F1298-0551 (Figure 35A). In the normalized graph, the signal increased more 
sharply for compounds F1298-0074 and F1298-0581, because the graph was indicative of 
the percent toxicity at varying concentrations (Figure 35B). The least toxic compounds 
were compounds F1298-0533 and F1298-0551, which was indicated by the nearly linear 
graphs for these compounds in the percent toxicity graph (Figure 35B).  
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B 
Figure 36: Toxicity of compounds F1298-0621, F1298-0587, and F1298-0522. 
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0522 showed no signal change (Figure 36A). The blanks, which did not contain any 
CBIs, were consistent with a lack of toxicity. The activity can be interpreted that 
compound F1298-0587 was toxic, with an LD50 value of 14.1 ± 2.0 µM, and compounds 
F298-0621 and F1298-0522 were very mildly toxic at the highest concentration tested. 
This interpretation can be made, because the luminescent signal decreased sharply for 
compound F1298-0587, and very slightly for compounds F298-0621 and F1298-0522 
(Figure 36A). In the normalized graph, the signal increased more sharply for compound 
F1298-0587, because the graph was indicative of the percent toxicity at varying 
concentrations (Figure 36B).  
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Figure 37: Toxicity of compounds D093-0045, D093-0086, and F1298-0025. 
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Compounds D093-0045 and D093-0086 decreased in the crude luminescent 
signal after 3 hours at higher concentrations, while compound F1298-0025 remained 
relatively consistent, even at higher concentrations (Figure 37A). Additionally, two 
graphs were added with vehicle DMSO treatment only as a control. The normalized data 
showed 100 percent toxicity at higher concentrations for compounds D0093-0045 and 
D093-0086, and only 10 to 20 percent toxicity for compound F1298-0025 (Figure 37B). 
The LD50 values could be calculated accurately for compounds D0093-0045 and D093-
0086, which were 10.1 ± 1.7 µM and 8.4 ± 1.4 µM, respectively. 
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Figure 38: Toxicity of compounds WL052410D, WL052510D, WL052510F, and 
WL052510H. 
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Compounds WL052410D, WL052510D, WL052510F, and WL052510H all 
decreased in crude luminescent signal after 3 hours at the highest concentration tested 
(Figure 38A). It can be concluded that these compounds showed low toxicity at a 
concentration of 11 µM, but were toxic at 22.5 µM (Figure 38B). Due to insufficient data 
points at higher concentrations, accurate LD50 values were unable to be calculated.  
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Figure 39: Toxicity of compounds WL052510M and WL052510K. 
 
 
 
Compound WL052510M, but not compound WL052510K, decreased in the crude 
luminescent signal after 3 hours at the highest concentration tested (Figure 39A). This 
result was confirmed by the normalized data in Figure 39B. Because of the insufficient 
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data at higher concentrations, no accurate LD50 values could be calculated for compound 
WL052510M, but toxicity was established at a concentration of 22.5 µM. 
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Figure 40: Toxicity of compounds WL052410G, WL052410K, WL052410N, and 
WL060110G.  
 
 
 
Compounds WL052410G, WL052410K, WL052410N, and WL060110G all 
decreased in the crude luminescent signal after 3 hours at higher concentrations (Figure 
40A). The normalized data confirmed that the toxicity was more than 90 percent, with 
respect to the controls for all compounds tested at a concentration of 22.5 µM (Figure 
40B). The calculation of the LD50 values was compromised, due to the missing data at 
higher compound concentrations for compounds WL052410G and WL060110G (Figures 
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40A and 40B). However, the LD50 values for compounds WL052410K and WL052410N 
were 12.5 ± 1.7 µM and 9.6 ± 1.6 µM, respectively. 
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Figure 41: Toxicity of compounds WL060110H, WL040710D, and WL042210G. 
 
 
 
Compounds WL060110H, WL040710D, and WL042210G all decreased in the 
crude luminescent signal after 3 hours at the highest concentration tested (Figure 41A). 
The normalized data showed a toxicity for compounds WL040710D and WL042210G of 
higher than 90 percent at 22.5 µM. In addition, the toxicity of compound WL060110H 
was approximately 60 percent at 22.5 µM. As mentioned before, the accurate calculation 
of the LD50 values was not possible, due to insufficient data. 
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Figure 42: Toxicity of compounds WL061410C, WL042210D, WL060310C, and 
WL061410K. 
 
 
 
Compounds WL061410C, WL042210D, WL060310C, and WL061410K all 
decreased in the crude luminescent signal after 3 hours at the highest concentration tested 
(Figure 42A); however, the crude luminescent signal for compounds WL042210D and 
WL060310C only slightly decreased at the highest concentration, indicating that these 
compounds were only weakly toxic. The normalized data confirmed this observation that 
compounds WL061410C and WL061410K were more toxic than compounds 
WL042210D and WL060310C (Figure 42B). Compound WL061410C was the only 
compound that reached 100 percent toxicity at the highest concentration, making it the 
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most toxic compound in the compound set (Figure 42B). Compound WL042210D had 
about 30 percent toxicity at the highest concentration tested, compound WL060310C had 
about 10 percent toxicity at the highest concentration tested, and compound WL061410K 
had about 70 percent toxicity at the highest concentration tested (Figure 42B). 
 
A 
 
B 
Figure 43: Toxicity of compounds WL042210G, WL042210K, and WL060110G. 
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WL060110G were significantly toxic. The LD50 values were 9.8 ± 1.0 µM, 11.4 ± 1.7 
µM, and 14.2 ± 6.2 µM, respectively.  
Another compound identified by HTS was compound GW 0742 (Figure 44). The 
toxicity of compound GW 0742 was determined twice in quadruplet, as depicted in 
Figure 45.  
 
 
 
 
 
Figure 44: Structure of compound GW 0742. 
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Figure 45: Toxicity of compound GW 0742. 
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The 2 measurements for compound GW 0742 show reproducible data. Figure 45 
consists of crude and normalized luminescence performed under identical conditions for 
compound GW 0742. The concentrations tested range from 100 µM to 0.195 µM. Both 
results showed that compound GW 0742 was only toxic at higher concentrations. The 
LD50 value determined was 47.5 ± 6.3 µM.  
The results of all compounds are summarized in Table 7 in Appendix A, which 
categorizes all of the tested compounds with respect to their toxicity and their 
corresponding activity in the transcription assay.  
 
Chapter 3.7: Discussion of the Results of the Cell Titer-Glo Luminescence Assay 
In total, 39 compounds were investigated with respect to their toxicity. Many different 
scaffolds were toxic, which is a concern with some of these molecules. As seen in the 
Gene BLAzer transcription inhibition assay, the class of 3-indolyl methanamines 
(compounds F0842-0039, F1217-0092, F1387-0028, F1387-0021, F1387-0036, F0743-
0032, F1387-0020, F1387-0034, and F1387-0022) was also identified as the superior 
class of irreversible inhibitors of the VDR-coactivator interaction and of partial toxicity. 
The results presented previously in this chapter are published in Nandhikonda et al. 29 
 The 3-indolyl methanamine class varied in aromatic substituents. Compound 
F0842-0039 had a phenol group; compound F1217-0092 had a para toluene group; 
compound F1387-0028 had a meta anisole group; compound F1387-0021 had a meta 
bromobenzene group; compound F1387-0036 had a para bromobenzene group; 
compound F0743-0032 had a para fluorobenzene group; compound F1387-0020 had a 
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para xylene group; compound F1387-0034 had a meta chlorobenzene group, and 
compound F1387-0022 had a meta fluorobenzene group.  
 Of these compounds, compound F1387-0036, which had a para bromobenzene 
group and an LD50 value of 21.5 µM, and compound F1387-0020, which had a para 
xylene group and an LD50 value of 11.7 µM, were the most active compounds with partial 
toxicity. The rest of the compounds in this class showed a high toxicity with low 
transcriptional activity. Of the remaining initial compounds, only compound F1298-0587 
and compound D093-0045 have only a slight potential, due to their transcriptional 
inhibition abilities and partial toxicity. Compound D093-0086 demonstrated high toxicity 
with an LD50 value of 8.4 µM. 
 Of the compounds synthesized from the 3-indoyl methanamines, compounds 
WL052410K (31c), which had a para methoxybenzene group and an LD50 value of 12.5 
µM; WL060110G (31d), which had a toluene group and an LD50 value of 16.9 µM; 
WL042210G (31h), which had an ortho methoxybenzene group and an LD50 value of 9.8 
µM; WL042210K (30h), which had a napthylbenzene group and an LD50 value of 11.4 
µM; and WL052410G (31b), which had a chlorobenzene group and an LD50 value of 14.2 
µM were the most active compounds.  
Compounds WL052410D (30c), which had an anisole group; WL052510D (30a), 
which had a benzene group; WL052510F (30d), which had a toluene group; WL052510H 
(30b), which had a chlorobenzene group; WL052510K (30e), which had a 
dimethylaniline group; WL052410G (31b), which lacked a methyl on the indolyl group; 
WL060110H (31f), which had a nitrobenzene group; WL061410C (32c), which had a 
thiobenzene group; WL061410K (30g), which had a methyl group; WL052510M (30f), 
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which had a nitrobenzene group; and WL040710D (31a), which had a benzene group, 
were highly toxic compounds. The rest had little to no toxicity and little to no 
transcriptional activity. 
 When considering small molecules for therapeutic use, the compounds that were 
most active in transcriptional inhibition and had partial toxicity have the greatest 
potential. Of the above listed compounds, compounds WL052410K (31c), which had a 
para methoxybenzene group and an LD50 value of 12.5 µM; WL060110G (31d), which 
had a toluene group and an LD50 value of 16.9 µM; WL042210G (31h), which had an 
ortho methoxybenzene group and an LD50 value of 9.8 µM; WL042210K (30h), which 
had a napthylbenzene group and an LD50 value of 11.4 µM; and WL052410G (31b), 
which had a chlorobenzene group and an LD50 value of 14.2 µM have the greatest 
potential for therapeutic uses. The characteristic that these compounds have in common, 
besides being 3-indolyl methanamines, is that they have electron-donating aryl 
substituents, or ortho, para directing groups, such as chlorine, which appear to be 
effective in inhibiting VDR-mediated transcription and appear to have partial 
cytotoxicity. 
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Chapter 4: VDR, SRC-2, and SRC-2-3 Protein Expression and 
Purification 
 
 
 
Chapter 4.1: Protein Expression 
Protein expression and purification were completed, in order to obtain the VDR-LBD, 
SRC-2, and SRC-2-3 proteins that were used for the co-IP and pull-down assays. To 
begin the protein expression, carbenicillin agar plates were prepared by mixing 20 grams 
of agar mix in 500 mL of water in a 2,000 mL autoclavable Erlenmeyer flask. The 
Erlenmeyer flask was then autoclaved. Once the liquid had cooled to room temperature, 
0.5 mL of carbenicillin was added to the flask, and the liquid was poured into the agar 
plates. The liquid in the plates was allowed to set, and the plates were stored in the 
refrigerator until needed.   
 Escherichia coli cells, strain database number AMKB037-B, containing plasmids 
for the vdr-LBD gene and carbenicillin resistance, were streaked onto the agar plates, and 
the plates were inverted and placed in an incubator at 37°C overnight. These E. coli then 
produced the VDR protein with only its ligand binding domain. The VDR-LBDmt DNA 
was kindly provided by D. Moras and cloned into pMAL-c2X vector (New England 
Biolabs). 
 BL-21 E. coli cells were heat shocked, in order to insert the SRC-2 and SRC-2-3 
genes into the cells. The vials of BL 21 cells were obtained from the -80°C freezer and 
thawed on ice for about 10 minutes. The 200 µL cell solution was mixed into a 
suspension, divided in half, and pipetted into 2 separate 1.5 mL microfuge tubes. To each 
of the microtubes, 1 µL of purified plasmid DNA to be uptaken was added. One 
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microtube contained the plasmid DNA for the SRC-2 protein, and the other microtube 
contained the plasmid DNA for the SRC-2-3 protein. The microtubes were incubated on 
ice for 30 minutes and heat shocked for exactly 40 seconds in an exactly 42°C tempered 
water bath. After the microtubes were removed from the water bath, they were incubated 
on ice again for another 2 minutes.  
Under sterile conditions in the biological fume hood, 900 µL of super optimal 
broth (SOC) growth medium with glucose added for catabolite repression was pipetted 
into each microtube. The microtubes were taped to a flask holder in the incubation 
shaker, and the cells were allowed to propagate for 1 hour at 37°C and 250 rpm. After the 
1 hour incubation, the cells were concentrated by microfugation for 1 minute at 6,000 
rpm. The supernatant was removed by pipette and discarded. The cells were resuspended 
in the remaining 100 µL of solution.  
  A 100 µL alliquot of each cell suspension, that is, SRC-2 and SRC-2-3, was used 
to inoculate 2 separate agar plates, one for the SRC-2 gene and the other for the SRC-2-3 
gene, for the desired expression in E. coli. The inoculated agar plates were sealed with 
parafilm, inverted, and placed in the incubation shaker at 37°C at the lowest shaking 
setting (25 rpm) overnight. Once the growth of the cell colonies was verified on the agar 
plates, a colony of the cells was used to inoculate a seed culture in Erlenmeyer flasks 
containing Luria Bertani (LB) broth and carbenicillin antibiotics. The inoculated seed 
culture was placed on the incubation shaker overnight at 37°C and 325 rpm. The LB 
broth growth media was prepared by adding 1,000 mL of tap water and 2 LB broth 
capsules to a 2,000 mL autoclavable Erlenmeyer flask and autoclaved. A quantity of 1 
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mL of carbenicillin antibiotics was added to the flasks when they cooled, in order to 
promote growth of bacteria with carbenicillin resistance only.  
 Approximately 25 mL of the VDR-LBD seed culture was pipetted into 8 separate 
2,000 mL Erlenmeyer flasks containing 1,000 mL of LB broth growth media and 
carbenicillin antibiotics. Only 2 separate 2,000 mL Erlenmeyer flasks were prepared with 
25 mL of the SRC-2 protein, and 2 for the SRC-2-3 protein. These flasks were placed in 
the incubator-shaker at 25°C and 325 rpm until an optical density of 0.3 to 0.6 was read 
on the spectrophotometer at 600 nm in a cuvette containing 1 mL of cell mixture.  
Once this optical density was reached, some 1 mL aliquots of the culture were 
frozen with 10 percent DMSO, placed in the -80°C freezer, and used in future protein 
expressions to prevent starting the protocol with E. coli colonies. After removing some 
aliquots of the cell culture, the cultures were induced with 1 mL of 0.2 mM of isopropyl 
β-D-1-thiogalactopyranoside, or IPTG, (10 mL of Milli-Q water in 0.478 grams of IPTG) 
and allowed to shake in the incubator-shaker overnight at 25°C and 325 rpm.  
IPTG triggers transcription of the lac operon, because it mimics the action of 
allolactose. IPTG is not degraded, allowing the concentration to remain constant, which 
allows transcription to occur at a steady rate.  
 The cells were harvested by centrifugation (JA-9.1000 rotor at 4°C at 6,000 rpm 
for 20 minutes). The pellet that remained after centrifugation was the E. coli cells 
containing the desired protein. The cells were placed into a 50 mL conical tube and 
frozen in the -80°C freezer until the protein purification process could be started.  
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Chapter 4.2: Protein Purification 
The first step in the protein purification process was the sonication of the cell pellet 
obtained from the protein expression. First, protease inhibitor was made by adding 1 
EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics) for every 50 mL of 1X 
dialysis buffer (20 mM Tris-base (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM sodium 
azide, 1 mM dithiothreitol (DTT), 10 percent glycerol, and 0.01 percent NP-40 
detergent).  
Protease inhibitors prevent proteolytic activity of enzymes, which are also known 
as proteases, present in E. coli. Proteases cleave the peptide bonds that link amino acids 
in proteins. In this particular protease inhibitor, serine, threonine, cysteine, aspartate, and 
glutamic acid proteases were inhibited, as well as metalloproteases. 
The cells were allowed to thaw on ice, and 30 mL of the protease inhibitor 
solution was pipetted into each of the conical tubes containing the cell pellet. The slurry 
was mixed until all of the cells were in suspension. The cell solution was placed into an 
ice and salt mixture and sonicated 3 times for 30 seconds each time at 40 percent 
amplitude, with a waiting period of at least 2 minutes between each sonication. After 
sonication, the cells were lysed by centrifugation using the JA-20 rotor, at 4°C and 
18,000 rpm for 45 minutes. The lysate was separated and cleared from the supernatant, 
which contained the desired VDR, SRC-2, or SRC-2-3 proteins from the cells. 
 The protein solutions were incubated with 3 mL per 50 mL of protein solution 
with affinity-tagged beads overnight on the rotisserie turner at 4°C. For VDR, maltose 
beads were used, for SRC-2, glutathione S-transferase (GST) beads were used, and for 
SRC-2-3, nickel-chelated beads were used (Figures 46 through 48).  
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Figure 46: Maltose binding protein (MBP) attached to an amylose resin. MBP is a 
member of the maltose and maltodextrin system of E.Coli, which is responsible for the 
catabolism of maltodextrins. Maltose can be immobilized by cross-linking to a solid-
support amylose resin. The purified MBP fusion protein can be dissociated and eluted by 
the addition of excess maltose (10 mM). 
 
 
 
 
 
Figure 47: Glutathione S-transferase (GST) bead. Glutathione is a tripeptide (Glu-Cys-
Gly) that is the specific substrate for GST. When reduced, glutathione is immobilized 
through its sulfhydryl group to a solid support, such as a cross-linked agarose bead. 
Glutathione can be used to capture GST-tagged proteins via the enzyme-substrate binding 
reaction. The purified GST-fusion protein can be dissociated and eluted from glutathione 
by addition of excess reduced glutathione (10 mM).  
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Figure 48: Histidine (His) nickel-nitrilotriacetic acid (NTA) resin. A string of 6 to 9 
histidine residues form an easily identifiable tag, which is fused to either the amino or 
carboxyl terminal. His-tagged proteins are easily purified and detected because the His-
tag binds to nickel, which is an immobilized metal ion. A chelating group, such as NTA, 
which is attached to a solid support, in this case, agarose, helps to immobilize the nickel 
ion, which then attaches to the His-tag. Elution of the His-tagged protein is done with 250 
mM imidazole solution. The imidazole replaces the nickel in the resin, which releases the 
protein. 
 
 
 
After the overnight incubation, the beads were separated from the supernatant by 
centrifugation at 4,000 rpm at 4°C for 20 minutes. The supernatant was decanted into a 
new 50 mL conical tube, and a 50 µL aliquot was pipetted into a microfuge tube, in order 
to resolve a sample on an SDS-PAGE gel. The beads were combined into one conical 
tube and 1X column buffer (20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 1 mM EDTA, 1 
mM sodium azide, and 9 mM β-mercaptol) was added to the conical tube, to a final 
volume of 30 mL. The conical tube was centrifuged at 4,000 rpm at 4°C for 5 minutes. 
The supernatant was again decanted into another conical tube, and a 50 µL aliquot was 
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pipetted into another microfuge tube. The beads were washed with column buffer and 
centrifuged again. These steps were repeated for a total of 5 washes. 
At this point, all of the SRC-2, SRC-2-3, and VDR proteins were left attached to 
their respective, solid support beads for later use in a co-IP and pull-down assay 
described in a later chapter. The fraction of the VDR protein attached to the maltose 
beads was eluted to yield VDR-LBD protein in solution.  
In order to elute the VDR protein from the maltose beads, the beads were 
transferred to a 15 mL conical tube, and 5 mL of the maltose solution, which was 10 mM 
maltose in column buffer, was added to the beads, followed by inversion of the conical 
tube. The conical tube was centrifuged at 4,000 rpm at 4°C for 5 minutes. The 
supernatant was decanted into another 15 mL conical tube, and a 50 µL aliquot was 
pipetted into a microfuge tube and set aside to be resolved on an SDS-PAGE gel. Another 
5 mL of the maltose elutant was added to the 15 mL conical tube containing the beads 
and inverted. The conical tube was centrifuged again at 4,000 rpm at 4°C for 5 minutes, 
the supernatant was again decanted into a separate 15 mL conical tube, and a 50 µL 
aliquot was removed into a separate microtube. This process was repeated for a total of 9 
elutions. 
Once all the elutions were complete, a Bradford assay was conducted on the 
supernatant, on washes 1 through 5, and on elutions 1 through 9. After the Bradford assay 
was complete, elutions 3 through 9 were combined, in order to concentrate the VDR 
protein further in a 10,000 kilodalton spin column by centrifugation at 4,000 rpm and 
4°C. After the protein was concentrated, the concentration was determined by a Bradford 
assay. The Bradford assay was followed by the resolution of the SDS-PAGE gel 
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containing all of the fractions, including the supernatant, washes, and elutions, in order to 
verify the presence and purity of the VDR protein. 
While the SDS-PAGE gel was resolving, the combined concentrated protein was 
added to a 10,000 kilodalton dialysis cassette, placed in 4 L of dialysis buffer (20 mM 
Tris-base (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM sodium azide, 1 mM DTT, 10 
percent glycerol, and 0.01 percent NP-40 detergent), and stirred overnight at 4°C . 
After an overnight dialysis, the protein was removed from the cassette, and 1 mL 
aliquots were pipetted into 1.5 mL microtubes. The microtubes containing the purified 
VDR protein were stored in the -80°C freezer and used as needed for subsequent assays.   
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Chapter 5.1.1: Experimental Procedure for the First Pull-Down Assay 
 
 
Chapter 5.1.1.1: Solid-Supported VDR 
 
The expression and purification of the VDR-LBD-MBP protein was described in chapter 
4. The difference between this protocol and the protocol previously described was that 
the current protocol was stopped before the elution step; thus, generating a solid-
supported VDR-LBD protein held to the solid support through the interaction of MBP 
and covalently bound amylose.  
 
Chapter 5.1.1.2: In situ-Generated SRC-2 
The Transcription and Translation (TNT from Promega) system is a single tube system, 
which couples transcription and translation reactions for eukaryotic in vitro translation. 
The system also combines T7 RNA polymerase, RNA polymerase nucleotides, salts, 
recombinant ribonuclease inhibitor, amino acids, and transcend biotinylated-lysyl-tRNA, 
which allowed for the generation of SRC-2 protein using an SRC-2 plasmid in a one 
hour.  
 
Chapter 5.1.1.3: Quantification of SRC-2-Biotin for the First Pull-Down Assay 
Into a 1.5 mL microfuge tube, 20 µL of the TNT quick master mix was pipetted, followed 
by 1 µL of methionine, 1 µL of biotinylated-lysyl-tRNA, and 1 µL of SRC-2 mutant 
plasmid containing 3 nuclear interaction domains (NIDs). The reaction tube was 
incubated at 30°C for time periods ranging from 60 to 90 minutes.  
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After the incubation, 23 µL of the TNT mixture was diluted in a 1 to 5 serial 
dilution using 1X SDS-PAGE MOPS running buffer (Invitrogen). Then, 5 µL of each of 
the 10 TNT mixture concentrations were added to 20 µL of 1X running buffer and 3 µL 
of loading buffer and dye (Invitrogen) in a microfuge tube. These microfuge tubes were 
incubated in a 70°C water bath for 10 minutes. After the incubation, 10 µL of each of the 
dilutions was pipetted into a lane on an SDS-PAGE gel (Invitrogen), and the gel was 
resolved at 200 V and 120 mA for 45 minutes in 4-morpholine-propane-sulfonic acid 
(MOPS) running buffer. The proteins resolved in the SDS-PAGE gel were transferred to 
a polyvinylidene fluoride (PVDF) membrane using the Bio-Rad Western blot instrument 
at 100 V and 350 mA for 1 hour in 1X tris-buffered saline (TBS) buffer.  
Before running the Western blot, the PVDF membrane was first incubated in 20 
mL of methanol for 15 seconds, then in 20 mL of Milli-Q water for 2 minutes, and 
finally, in 20 mL of TBS buffer for 5 minutes. In the meantime, 2 filter paper sheets were 
incubated in transfer buffer for 30 seconds. The Western transfer apparatus was 
assembled with the SDS-PAGE gel closest to the cathode terminal and blotted at 100 V 
and 350 mA for 1 hour in transfer buffer, in order to transfer the SRC-2-biotin protein 
from the SDS-PAGE gel to the PVDF membrane (Figure 50).  
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Figure 51: Colorimetric alkaline phosphatase assay. 
 
Figure 52 shows the intensities of different concentrations of SRC-2 generated by 
the TNT system. The ideal concentration of SRC-2-biotin protein was found to be the 1 
to 5 dilution of TNT mixture, as shown in lane 1b of Figure 52. In lane 1c of Figure 52, 
SRC-2 was still visible, but very faint.  
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Figure 52: Stained PVDF membrane. 
 
 
 
Chapter 5.2: Second Pull-Down Assay: Evaluating VDR-CBI, WL042210D (32a), 
Inhibition 
After the optimal SRC-2 protein concentration was determined, this protocol was 
performed in the presence of compound WL042210D (32a), which was identified as a 
potential CBI of the VDR-SRC-2 interaction; therefore, SRC-2-biotin was generated, as 
mentioned in the previous protocol, and used in 5 different experimental conditions, as 
summarized in Tables 2A through 2E. 
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Table 2A: Condition 1: High Concentration of CBI (200 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR Beads  5 µL   100 µL 
X VDR Ligand 10 mM 0.5 µL  50 µM 100 µL 
X WL042210D (32a) 10 mM 2 µL  200 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  89 µL   100 µL 
Table 2B: Condition 2: Medium Concentration of CBI (50 µM) 
Ad
d 
Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR Beads  5 µL   100 µL 
X VDR Ligand 10 mM 0.5 µL  50 µM 100 µL 
X WL042210D (32a) 10 mM 0.5 µL  50 µM 100 µL 
X DMSO  1.5 µL  2% 100 µL 
X FP Buffer  89 µL   100 µL 
Table 2C: Condition 3: Low Concentration of CBI (1 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR Beads  5 µL   100 µL 
X VDR Ligand 10 mM 0.5 µL  50 µM 100 µL 
X WL042210D (32a) 100 µM 1 µL  1 µM 100 µL 
X DMSO  1 µL  2% 100 µL 
X FP Buffer  89 µL   100 µL 
Table 2D: Condition 4: VDR-SRC-2 Interaction (Negative Control; No CBI) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR Beads  5 µL   100 µL 
X VDR Ligand 10 mM 0.5 µL  50 µM 100 µL 
 WL042210D (32a) 10 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  89 µL   100 µL 
Table 2E: Condition 5: No VDR Ligand (Positive Control; No CBI or VDR Ligand) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR Beads  5 µL   100 µL 
 VDR Ligand 10 mM 0.5 µL  50 µM 100 µL 
 WL042210D (32a) 10 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  89 µL   100 µL 
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In summary, the first microfuge reaction tube contained the CBI at a 
concentration of 200 µM. The second microfuge reaction tube contained the CBI at a 
concentration of 50 µM. The third microfuge reaction tube contained the CBI at a 
concentration of 1 µM. The fourth microfuge reaction tube was the negative control, 
which had no CBI. The fifth microfuge reaction tube was the positive control, which had 
no CBI or VDR ligand. 
 The 5 reactions in the microfuge tubes were incubated on the shaker at room 
temperature for 30 minutes, followed by the addition of 8 µL of the TNT reaction 
mixture. After an additional incubation on the shaker for 30 minutes at room temperature, 
the microfuge tubes were centrifuged for 10 seconds at 3,000 rpm, in order to force the 
liquid to the bottom of the microfuge tube. Then, 100 µL of each solution was pipetted 
into separately labeled micro spin columns. The spin columns were centrifuged at 3,000 
rpm for 30 seconds. After centrifugation, 100 µL of FP buffer was added to each of the 5 
filters of the spin columns, and centrifuged again at 3,000 rpm for 30 seconds. The trap 
for the bottom of the spin column was exchanged for a clean trap, and 10 µL of a 10 mM 
maltose solution (36 mg of maltose in 10 mL of FP buffer) was pipetted into the filters of 
each of the 5 spin columns. The maltose solution eluted VDR from the amylose beads, 
because VDR had an MBP affinity tag. The spin columns were incubated at room 
temperature for 5 minutes with the maltose solution before being centrifuged again at 
5,000 rpm for 2 minutes. Approximately 5 µL of the liquid was recovered for each 
reaction. The liquid was pipetted into lanes of an SDS-PAGE gel, which were visualized 
by a Western blot, as described in the previous protocol. 
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Unfortunately, no bands were detected in the first pull-down assay conducted with 
compound WL042210D (32a), as seen in Figure 53. The assay was repeated, doubling 
the volumes in the TNT reaction mixture and adding 12 µL of TNT reaction mix to each 
microfuge tube reaction; however, also in that case, no band were detected (gel not 
shown).  
 
 
 
 
 
 
 
 
 
 
Figure 53: Stained PVDF membrane of the 5 pull-down reactions using VDR-CBI, 
WL042210D (32a).   
 
 
 
Chapter 5.3: Third Pull-Down Assay using a Solid-Supported SRC-2 and VDR-LBD 
for the Identification of VDR-CBIs 
 
The previously described pull-down assay protocol was modified using SRC-2 
coactivator protein attached to a solid support, instead of the VDR protein (Figure 54). 
Two different SRC-2 proteins were evaluated. 
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Table 3A: Condition 1: High Concentration of CBI (200 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 113 µM 9 µL  10.17 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL042210D (32a) 10 mM 2 µL  200 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  73 µL   100 µL 
Table 3B: Condition 2: Medium Concentration of CBI (50 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 113 µM 9 µL  10.17 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL042210D (32a) 10 mM 0.5 µL  50 µM 100 µL 
X DMSO  1.5 µL  2% 100 µL 
X FP Buffer  73 µL   100 µL 
Table 3C: Condition 3: Low Concentration of CBI (1 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 113 µM 9 µL  10.17 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL042210D (32a) 100 µM 1 µL  1 µM 100 µL 
X DMSO  1 µL  2% 100 µL 
X FP Buffer  73 µL   100 µL 
Table 3D: Condition 4: VDR-SRC-2 Interaction (Negative Control; No CBI) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 113 µM 9 µL  10.17 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
 WL042210D (32a) 10 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  73 µL   100 µL 
Table 3E: Condition 5: No VDR Ligand (Positive Control; No CBI or VDR Ligand) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 113 µM 9 µL  10.17 µM 100 µL 
 Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
 WL042210D (32a) 10 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  73 µL   100 µL 
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In summary, two sets of five microfuge reaction tubes were prepared. One set was 
assayed with SRC-2 with the 3 NIDs, and the second set was assayed with the SRC-2-3 
with 1 NID. For each set, the first microfuge reaction tube contained the CBI, 
WL042210D (32a), at a concentration of 200 µM. The second microfuge reaction tube 
contained the CBI at a concentration of 50 µM. The third microfuge reaction tube 
contained the CBI at a concentration of 1 µM. The fourth microfuge reaction tube was the 
negative control, which had no CBI. The fifth microfuge reaction tube was the positive 
control, which had no CBI or VDR ligand. 
 
Chapter 5.3.1: Experimental Procedure for the Third Pull-Down Assay 
All reactions were incubated on the shaker at room temperature for 2 hours, followed by 
the addition of 15 µL of beads and another incubation period of 30 minutes at room 
temperature on the shaker. Upon completion of the second incubation, the 10 microfuge 
reaction tubes were centrifuged for 10 seconds at 3,000 rpm, in order to force the liquid 
to the bottom of the microfuge tube. Then, 100 µL of VDR-TNT mixture from each 
microfuge tube was pipetted into separately labeled micro spin columns. The spin 
columns were centrifuged at 3,000 rpm for 30 seconds. After centrifugation, 100 µL of 
FP buffer was added to each of the 10 filters of the spin columns, and centrifuged again at 
3,000 rpm for 30 seconds. The trap for the bottom of the spin column was exchanged for 
a clean trap, and 20 µL of a 10 mM glutathione solution (30.7 mg of maltose in 10 mL of 
FP buffer) was pipetted into the filters of each of the 5 GST bead spin columns, and 20 
µL of a 250 mM imidazole solution (85 mg of imidazole in 10 mL of FP buffer) was 
pipetted into the filters of each of the 5 nickel bead spin columns. The spin columns were 
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incubated at room temperature for 10 minutes with their respective solution before being 
centrifuged at 5,000 rpm for 2 minutes.  
Approximately 10 µL of the VDR mixture was recovered after centrifugation, and 
3 µL of the loading buffer and dye was added to each of the 10 microfuge reaction tubes. 
The solutions were mixed by pipette and incubated in a water bath at 70°C for 10 minutes 
to denature the protein. The microfuge reaction tubes were centrifuged again at 3,000 
rpm for 30 seconds, and 13 µL from each microfuge reaction tube was pipetted into 
separate lanes of an SDS-PAGE gel in a gel box containing 1X MOPS running buffer. 
The gel was resolved for 45 minutes at 200 V and 120 mA, removed from the plastic 
casing, and rinsed in Milli-Q water 3 times for 5 minutes each time. The gel was 
incubated for 2 hours using Simply Blue Stain (Invitrogen) and rinsed overnight in Milli-
Q water. The image in Figure 55 was obtained from the gel. 
 
 
 
 
 
 
 
 
 
 
90 
 
 
Chapter 5.3.2: Results of the Third Pull-Down Assay 
 
 
Figure 55: SDS-PAGE gel of the VDR-coactivator pull-down assay using compound 
WL042210D (32a). 
 
 
 
The first column on the left-hand side was the See Blue 2 ladder (Invitrogen). 
Columns 3a through 3e contained the samples of the SRC-2-3 with 1 NID, and columns 
4a through 4e contained the SRC-2 with the 3 NIDs. VDR was used as control. The 
intensity of the VDR bands changed significantly for the SRC-2 experiment. With 
increasing concentrations of compound WL042210D (32a), there was a change among 
the SRC-2 lanes, 4a, 4b, and 4c, with 4c being the most visible band. A similar change 
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was not observed for the SRC-2-3 lanes, indicating that SRC-2-3 did not bind to VDR, 
but SRC-2 did. 
 
Chapter 5.3.3: The Fourth Pull-Down Assay with CBIs WL052410G (31b) and 
CBT-1 
 
Based on the results from the third pull-down assay, 5 experiments each were repeated 
with 2 other VDR-CBIs, compounds WL052410G (31b) and CBT-1, with the conditions 
described in Tables 4A through 4E. 
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Table 4A: Condition 1: High Concentration of CBI (200 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 88 µM 11.5 µL  10.12 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b)/CBT-1 10 mM 2 µL  200 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  65.5 µL   100 µL 
Table 4B: Condition 2: Medium High Concentration of CBI (100 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 88 µM 11.5 µL  10.12 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b)/CBT-1 10 mM 1 µL  100 µM 100 µL 
X DMSO  1 µL  2% 100 µL 
X FP Buffer  65.5 µL   100 µL 
Table 4C: Condition 3: Medium Low Concentration of CBI (50 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 88 µM 11.5 µL  10.12 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b)/CBT-1 10 mM 0.5 µL  50 µM 100 µL 
X DMSO  1.5 µL  2% 100 µL 
X FP Buffer  65.5 µL   100 µL 
Table 4D: Condition 4: Low Concentration of CBI (1 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 88 µM 11.5 µL  10.12 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b)/CBT-1 100µM 1 µL  1 µM 100 µL 
X DMSO  1 µL  2% 100 µL 
X FP Buffer  65.5 µL   100 µL 
Table 4E: Condition 5: VDR-SRC-2 Interaction (Negative Control; No CBI) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 88 µM 11.5 µL  10.17 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
 WL052410G (31b)/CBT-1 10 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  65.5 µL   100 µL 
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The microfuge reaction tubes were incubated on the shaker at room temperature 
for 2 hours. After the 2 hour incubation, 15 µL of GST beads with SRC-2 coactivator 
were added to all of the 10 microfuge reaction tubes. These 10 microfuge reaction tubes 
were incubated for another 30 minutes at room temperature on the shaker. The previous 
procedure for the spin columns used for the GST beads was repeated for these 10 
microfuge reaction tubes. Upon elution of the GST beads with 20 µL of 10 mM 
glutathione solution, 10 µL of the solution from each microfuge reaction tube was 
recovered. The recovered solution was then mixed with 3 µL of loading dye and resolved 
on an SDS-PAGE gel, as seen in Figure 56.  
 
 
Figure 56: SDS-PAGE gel of the VDR-coactivator pull-down assay using compounds 
WL052410G (31b) and CBT-1. 
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Table 5A: Condition 1: High Concentration of CBI (200 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b) 10 mM 2 µL  200 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 5B: Condition 2: Medium High Concentration of CBI (100 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b) 10 mM 1 µL  100 µM 100 µL 
X DMSO  1 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 5C: Condition 3: Medium Low Concentration of CBI (50 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b) 10 mM 0.5 µL  50 µM 100 µL 
X DMSO  1.5 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 5D: Condition 4: Low Concentration of CBI (1 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
X WL052410G (31b) 100 µM 1 µL  1 µM 100 µL 
X DMSO  1 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 5E: Condition 5: VDR-SRC-2 Interaction (Negative Control; No CBI) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X Calcitriol 10 µM 1 µL  0.1 µM 100 µL 
 WL052410G (31b) 10 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
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Table 5F: Condition 6: No VDR Ligand (Positive Control; No CBI or VDR Ligand) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
 Calcitriol 10 µM 0 µL  0.1 µM 100 µL 
 WL052410G (31b) 10 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  69 µL   100 µL 
Table 5G: Condition 7: SRC-2 Beads Only (SRC-2 Protein Only) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
 VDR 106 µM 0 µL  10.07 µM 100 µL 
 Calcitriol 10 µM 0 µL  0.1 µM 100 µL 
 WL052410G (31b) 10 mM 0 µL  0 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  80 µL   100 µL 
Table 5H: Condition 8: VDR Protein Only  
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 0.2 µL  2.12 µM 10 µL 
 Calcitriol 10 µM 0 µL  0.1 µM 10 µL 
 WL052410G (31b) 10 mM 0 µL  0 µM 10 µL 
 DMSO  0 µL  2% 10 µL 
X FP Buffer  0 µL   10 µL 
X Milli-Q Water  10 µL   10 µL 
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Chapter 5.4.1: Experimental Procedure for the First Co-Immunoprecipitation Pull-
Down Assay 
 
The reaction conditions represented in Tables 5A through 5F were incubated at room 
temperature on the shaker for 2 hours. After the 2 hour incubation, 15 µL of GST beads 
were added, as well as SRC-2 protein only. After incubating the microfuge tubes for 30 
minutes at room temperature and a wash step, the protein was eluted from the solid 
support and resolved on an SDS-PAGE gel, as described previously. A Western blot was 
developed from the SDS-PAGE gel, according to the previously described protocol; 
however, the Western membrane was dried overnight after the protein transfer. The next 
day, the Western membrane was incubated in methanol for 15 seconds, followed by 
incubation in a 3 percent bovine serum albumin (BSA) blocking buffer solution (0.6 
grams of BSA in 19.40 mL of TBST buffer) on a rocking apparatus for 60 minutes.  
Then, a 1 to 10,000 dilution of primary antibody solution of anti-MBP 
monoclonal antibody (2 µL of primary VDR antibody in 20 mL of TBST buffer; New 
England Biolabs) was prepared. The Western membrane was incubated for 60 minutes in 
the primary antibody solution, washed 3 times in TBST buffer for 5 minutes each wash, 
and incubated with a 1 to 300 dilution of fluorescent secondary antibody solution of goat 
anti-mouse IgG-TR (66.7 µL of secondary antibody in 20 mL of TBST buffer; Santa 
Cruz Biotechnology) on a rocking apparatus for 60 minutes. After 3 more washes with 
TBST buffer for 5 minutes each wash, the Western membrane was imaged on the Bio-
Rad laser imager. 
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Chapter 5.4.1.1: Antibodies used for the Co-IP Pull-Down Assay 
The basic structural unit of most mammalian antibodies is a glycoprotein of four 
polypeptide chains; two of which are light chains, and two of which are heavy chains, 
that are connected by disulfide bonds (Figure 59). The hinge region permits flexibility 
between the two arms of the Y-shaped antibody molecule, allowing them to open and 
close to accommodate binding. 
 
 
 
 
 
 
 
Figure 58: Basic structure of an antibody.  
 
The primary antibody, anti-MBP monoclonal antibody, is a murine, anti-maltose 
binding protein antibody with an isotype of IgG2a. Immunoglobulin G (IgG) antibodies 
are distinguished by their two heavy γ chains. The heavy chains also determine the 
functional activity of the antibody. This particular antibody was used to detect MBP in 
Western blots. 
 The secondary antibody, goat anti-mouse IgG-TR, reacts with the heavy chains of 
the primary antibody and is conjugated with Texas Red fluorophore, which allows for 
fluorescent detection on a laser imager.  
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Chapter 5.4.2: Results of the First Co-Immunoprecipitation Pull-Down Assay 
 
 
 
 
 
 
Figure 59: First co-IP VDR-coactivator pull-down assay using compound WL052410G 
(31b). 
 
 
 
Control experiments indicated that SRC-2 bound to VDR in the presence of the calcitriol, 
as seen in Figure 59, lane 7e, but not in the absence of calcitriol, as seen in Figure 59, 
lane 7f. The VDR-SRC-2 interaction was blocked in a dose-dependent manner by 
compound WL052410G (31b), which can be seen in Figure 59, lanes 7b through 7d. 
Although significant inhibition of the VDR-SRC-2 interaction was observed at a 
concentrations of 50 µM and 100 µM of compound WL052410G (31b), a residual 
interaction between VDR and SRC-2 could still be detected at these concentrations, due 
to unspecific binding or insufficient washing.  
Interestingly, at a very high concentration of compound WL052410G (31b), the 
VDR-SRC-2 interaction was still observed, which was most likely caused by the cross-
linking of this irreversible inhibitor.  
 
 
7a 7b 7c 7d 7e 7f      7g  7h 
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Chapter 5.4.3: The Second Co-Immunoprecipitation Pull-Down Assay 
To optimize the conditions of the first co-IP pull-down assay, the following changes were 
made to the protocol. First, 15 µL of glutathione solution was used to elute the GST 
beads, instead of the previous amount of 2 µL. Additionally in this step, the spin columns 
were centrifuged at 14,000 rpm for 5 minutes, which eluted 13 to 15 µL of protein 
complex, instead of the 10 µL previously eluted. Furthermore, 5 percent dried milk 
solution (1 gram of dried milk in 19 mL of TBST buffer) was used to block the 
membrane, instead of the 3 percent BSA solution. Finally, a 1 to 400 dilution of the 
secondary antibody solution (50.0 µL of secondary antibody in 20 mL of TBST buffer) 
was used instead of a 1 to 300 dilution.  
Overall, an improvement was observed with the modified procedure. Unspecific 
binding was not observed for the negative and positive control reactions, as seen in 
Figure 60 in lanes 8f and 8g, respectively. Also, full inhibition of VDR-coactivator 
binding was observed at a concentration of 100 µM of compound WL052410G (31b), as 
seen in lane 8b.  
 
 
 
 
 
Figure 60: Second co-IP VDR-coactivator pull-down assay using compound 
WL052410G (31b). 
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Chapter 5.5: Co-Immunoprecipitation Pull-Down Assay using a Solid-Supported 
SRC-2 and VDR-LBD for the Identification of a Reversible VDR-CBI, Compound 
GW 0742 
 
Compound GW 0742 was identified during an HTS as a potential CBI of the VDR-SRC-
2 coactivator interaction. Compound GW 0742 was introduced by GlaxoSmithKline in 
2003 as a highly selective agonist for PPARδ.44 Since then, compound GW 0742 has 
been investigated in cell-based assays and in vivo assays, in order to understand the role 
of PPARδ in hypertension,45, 46 diabetes,47, 48 inflammation,49, 50 obesity,51 and cancer.52-54 
Interestingly, PPAR agonists have been shown to inhibit the transcription of the VDR 
target gene, CYP24A1, in the presence of 1,25-(OH)2D3;55 therefore, the ability of 
compound GW 0742 to inhibit the interaction VDR-SRC-2 coactivator was analyzed 
with the developed co-IP pull-down assay, and determined to inhibit the interaction in a 
dose-dependent manner.   
 
 
 
 
Figure 61: Chemical structure of compound GW 0742.  
 
 
 
The following reactions with compound GW 0742 were performed at 
concentrations of 120 µM, 80 µM, 50 µM, 20 µM, 10 µM, 1 µM, and 0.1 µM, as 
summarized in Tables 6A through 6I. The concentration used previously for the band of 
the VDR protein only was halved from 2.12 µM in the previous protocols to 1.06 µM in 
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this protocol. Additionally, a synthetic VDR agonist ligand, LG 19017860, was used 
instead of calcitriol ligand.  
Table 6A: Condition 1: Concentration One of CBI (120 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
X GW 0742 6 mM 2 µL  120 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 6B: Condition 2: Concentration Two of CBI (80 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
X GW 0742 2 mM 2 µL  80 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 6C: Condition 3: Concentration Three of CBI (50 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
X GW 0742 0.67 mM 2 µL  50 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 6D: Condition 4: Concentration Four of CBI (20 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
X GW 0742 0.22 mM 2 µL  20 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
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Table 6E: Condition 5: Concentration Five of CBI (10 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
X GW 0742 74 µM 2 µL  10 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
 
Table 6F: Condition 6: Concentration Six of CBI (1 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
X GW 0742 25 µM 2 µL  1 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
 
Table 6G: Condition 7: Concentration Seven of CBI (0.1 µM) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
X GW 0742 8 µM 2 µL  0.1 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 6H: Condition 8: VDR-SRC-2 Interaction (Negative Control; No CBI) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
X LG 190178 100 µM 1 µL  1 µM 100 µL 
 GW 0742 0 mM 0 µL  0 µM 100 µL 
X DMSO  2 µL  2% 100 µL 
X FP Buffer  68 µL   100 µL 
Table 6I: Condition 9: No VDR Ligand (Positive Control; No CBI or Ligand) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 9.5 µL  10.07 µM 100 µL 
 LG 190178 0 µM 0 µL  0 µM 100 µL 
 GW 0742 0 mM 0 µL  0 µM 100 µL 
X DMSO  3 µL  2% 100 µL 
X FP Buffer  69 µL   100 µL 
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Table 6J: Condition 10: SRC-2 Beads Only (SRC-2 Protein Only) 
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
 VDR 0 µM 0 µL  0 µM 100 µL 
 LG 190178 0 µM 0 µL  0 µM 100 µL 
 GW 0742 0 mM 0 µL  0 µM 100 µL 
 DMSO  0 µL  2% 100 µL 
X FP Buffer  80 µL   100 µL 
Table 6K: Condition 11: VDR Protein Only  
Add Reagent Initial 
Concentration 
Initial 
Volume 
 Final 
Concentration 
Final 
Volume 
X VDR 106 µM 0.1 µL  1.06 µM 10 µL 
 LG 190178 0 µM 0 µL  0 µM 10 µL 
 GW 0742 0 mM 0 µL  0 µM 10 µL 
 DMSO  0 µL  2% 10 µL 
 FP Buffer  0 µL   10 µL 
X Milli-Q Water  10 µL   10 µL 
 
 
From this point, the same protocol used in the previous co-IP assay was applied 
for CBI incubation, spin column purification, resolution on the SDS-PAGE gel, the 
Western blot transfer, and antibody incubation of the Western blot membrane. The 
following results in Figure 62 were obtained. 
 
 
Lane 1 2 3 4 5 6 7 8 9 10 
GW 0742 120 80 50 20 10 1 0.1 - - - 
VDR-LBD + + + + + + + + + - 
SRC-2 + + + + + + + + + + 
LG 
190178 + + + + + + + + - - 
 
Figure 62: Inhibition of the VDR−SRC-2 interaction by compound GW 0742, analyzed 
by a co-IP pull-down assay. 
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Control experiments indicated that SRC-2 bound to VDR in the presence of LG 
190178 ligand, as seen in Figure 62, lane 8, but not in the absence of the LG 190178 
ligand, as seen in Figure 62, lane 9. The faint bands for SRC-2 in the absence of VDR 
ligand and in the absence of VDR were caused by the unspecific binding between the 
VDR antibody and the SRC-2 beads. The VDR−SRC-2 interaction was blocked in a 
dose-dependent manner by compound GW 0742, as seen in Figure 62, lanes 1 through 7. 
Although significant inhibition of the VDR−SRC-2 interaction was observed at the 
concentrations of 120 µM and 80 µM of compound GW 0742, residual bands could still 
be detected, partially due to unspecific binding of the VDR antibody to SRC-2 beads, as 
observed for the controls.  
 
Chapter 5.6: Discussion of the Results of the Co-Immunoprecipitation Pull-Down 
Assays 
 
When considering small molecule CBIs for the co-IP pull-down assays, the compounds 
that were most active in transcriptional inhibition and had partial toxicity were selected. 
This was compound WL052410G (31b), bearing a chlorobenzene group, and compound 
WL042210D (32a), bearing an aniline group and a methyl group attached to the nitrogen 
of the indolyl group. The results are published in Nandhikonda et al.29  
The first pull-down assay determined that a 1 to 5 serial dilution of the TNT 
mixture was the most useful concentration in this assay. This assay was then performed 
in the presence of compound WL042210D (32a), which was identified as an inactive CBI 
of the VDR-coactivator interaction. Since no bands were detected in this experiment or 
the experiment using double the volume of TNT reaction mixture, the protocol was 
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modified to use one of the two SRC coactivator proteins as the protein attached to a solid 
support, instead of the VDR protein. It was determined that the SRC-2 protein with all 3 
NIDs, instead of the SRC-2 protein with only 1 NID, or SRC-2-3, was effective in 
immunoprecipitating the VDR-small molecule CBI interaction.  
After it was determined that the SRC-2 with 3 NIDs was the most effective 
protein for immunoprecipitation, 2 other VDR-CBIs, compounds WL052410G (31b) and 
CBT-1, were tested. The results showed that compound CBT-1 was slightly more active 
at inhibition than compound WL052410G (31b), which might be due to unspecific 
binding or the presence of an overlapping band from the SRC-2 expression. The results 
were verified for compound WL052410G (31b) by performing an additional experiment 
using 2 VDR-specific antibodies in the first co-immunoprecipitation pull-down assay.  
The control experiments indicated that SRC-2 bound to VDR in the presence of 
calcitriol, but not in the absence of calcitriol. The VDR-SRC-2 interaction was blocked in 
a dose-dependent manner by compound WL052410G (31b). Although significant 
inhibition of the VDR-SRC-2 interaction was observed at a concentrations of 50 µM and 
100 µM of compound WL052410G (31b), a residual interaction between VDR and SRC-
2 could still be detected at these concentrations, due to unspecific binding, insufficient 
washing, or the cross-linking of this irreversible inhibitor.  
A few changes were made in the protocol to eliminate the residual interaction 
between VDR and SRC-2 at higher concentrations. These included adding 15 µL of 
glutathione solution to elude the GST beads, instead of the previous amount of 2 µL, 
centrifuging the spin columns at 14,000 rpm for 5 minutes, which eluted 13 to 15 µL of 
protein complex, instead of the 10 µL previously eluted, adding 5 percent dried milk 
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solution (1 gram of dried milk in 19 mL of TBST buffer) to block the Western 
membrane, instead of the 3 percent BSA solution, and performing a 1 to 400 dilution of 
the secondary antibody solution (50.0 µL of secondary antibody in 20 mL of TBST 
buffer), instead of a 1 to 300 dilution. By making these changes, unspecific binding was 
eliminated for the reactions. Also, full inhibition of VDR-coactivator binding was 
observed at a concentration of 100 µM of compound WL052410G (31b).  
Compound GW 0742 was identified during an HTS as a potential CBI of the 
VDR-SRC-2 coactivator interaction. This compound was used in the developed co-IP 
pull-down assay at concentrations that varied from 120 µM to 0.1 µM. Two additional 
changes to the protocol included changing the concentration of the VDR protein only 
from 2.12 µM to 1.06 µM and using a synthetic LG 19017860 ligand, instead of calcitriol.  
SRC-2 was shown to bind to VDR in the presence of LG 190178 ligand, but not 
in the absence of the ligand. The faint bands for SRC-2 in the absence of ligand and in 
the absence of VDR were caused by the unspecific binding between the VDR antibody 
and the SRC-2 beads. The VDR-SRC-2 interaction was shown to be blocked in a dose-
dependent manner by compound GW 0742. Although significant inhibition of the VDR-
SRC-2 interaction was observed at the concentrations of 120 µM and 80 µM of 
compound GW 0742, residual bands could still be detected, partially due to unspecific 
binding of the VDR antibody to SRC-2 beads. The results have been recently published 
in Biochemistry.56  
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Appendix 
 
Table 7: Summary of the compounds tested, with respect to their ability to inhibit VDR-
mediated transcription using the Gene BLAzer assay, as well as their cytotoxicity, which 
was determined by the Cell Titer-Glo luminescence assay. All results are given in 
micromolar concentrations. 
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